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Gene editing of BTK using CRISPR/Cas9 to study drug resistance in 
acute myeloid leukaemia 
By Melanie Märken 
 
Acute myeloid leukaemia (AML) has a current poor 5-year survival rate of only 27%, 
making the finding of new therapeutic avenues for treatment crucial. 
Bruton’s tyrosine kinase (BTK) is best known for its role in B-cell receptor signalling 
but is found to be expressed and constitutively phosphorylated in AML cell lines and 
patient-derived cells. Targeting BTK in B-cell malignancies with small molecule BTK 
inhibitor ibrutinib is clinically effective, however a small proportion of CLL and MCL 
relapse during the therapy and become refractory to ibrutinib. This resistance is mainly 
due to a cysteine to serine mutation in BTK at position 481 (C481S) that disrupts the 
irreversible, covalent binding between ibrutinib and the protein. As little is known 
about the role of BTK and its potential as a therapeutic target in AML, we studied the 
effects and functional consequences of pharmacological inhibition of BTK using 
ibrutinib in AML cell lines. Using the CRISPR/Cas9 system we generated the 
BTKC481S mutation in AML cell lines to explore the functional impact of this mutation 
on ibrutinib treatment as well as other related protein networks. Whilst no effect of 
ibrutinib on cell proliferation and viability was observed in a cell culture model using 
THP-1 cells, we demonstrate that the BTKC481S mutation led to reduced ibrutinib 
binding affinity as well as reversible binding compared to irreversible binding 
observed in BTKWT cells. BTK inhibition correlated with a decrease in p-
PLCγ2(Y1217) but had no observable effect on p-AKT(S473) or p-
p42/44(T202/Y204). Kinase substrate enrichment analysis showed a decrease in 
NEK2 activity and increased activity in kinases belonging to the RSK family in THP-
1 BTKWT and BTKC481S cells. An increase in abundance of PKC family members was 
also seen in THP-1 BTKC481S cells. 
Taken together this data demonstrates the CRISPR/Cas9 system can be utilised to 
model and study drug resistance mechanisms. 
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1.1 Acute myeloid leukaemia 
1.1.1 Normal Haematopoiesis 
Haematopoiesis describes the process of blood cell formation with the haematopoietic 
stem cell (HSC) being at the top of the hierarchy. Haematopoiesis occurs in two waves, 
the primitive wave and the definitive wave (Galloway & Zon, 2003). The primitive 
wave, also called primitive erythropoiesis, originates in the yolk sac and results in the 
development of erythrocytes and macrophages (Palis & Yoder, 2001). This wave 
occurs only once from mesoderm cells during early foetal development for the purpose 
of tissue oxygenation (Palis, 2014). Even though the primitive wave is transitory, 
erythroid progenitors are not pluripotent or capable of renewal. Like the primitive 
wave, the definitive wave originates in the yolk sac but transitions into the liver and 
finally into the bone marrow, thymus and spleen (Jagannathan-Bogdan & Zon, 2013). 
The definitive wave involves the production of all haematopoietic lineages and derives 
from haematopoietic stem cells. HSCs have long-term self-renewal capability and 
divide into multipotent and lineage-restricted progenitor populations (Kondo et al., 
2003; Weissman, 2000).  
 
Common myeloid progenitor cells can differentiate into erythrocytes, granulocytes, 
macrophages, platelets and dendritic cells. Lymphoid multipotent progenitor cells can 
differentiate into B-cells, T-cells, natural killer cells and also dendritic cells (Figure 
1.1).  
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Figure 1.1 Normal haematopoiesis 
Diagram of normal haematopoiesis in adults with the multipotent stem cell 
differentiating into a common myeloid and lymphoid progenitor that gives rise to 
multiple lineages. 
Reprinted by permission from Springer Nature [Nature Reviews Cancer, MYB function 
in normal and cancer cells, (Ramsay & Gonda, 2008)] 
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1.1.2 Acute myeloid leukaemia 
Haematological malignancies (HMs) are a group of blood cancers that arise from cells 
originating in the bone marrow. HMs have previously been subdivided into 4 groups: 
leukaemias, Hodgkin lymphomas, non-Hodgkin lymphomas and myelomas. More 
recently the World Health Organization (WHO) has further categorized HMs into over 
60 disease subtypes according to their cell lineage, genetic abnormalities and clinical 
features (Swerdlow et al., 2008).   
 
Acute myeloid leukaemia (AML) is a haematological malignancy arising from genetic 
alterations in normal HSCs (Kumar, 2011). These alterations disrupt the generation of 
mature blood cells resulting in excessive proliferation of a clonal population of 
abnormal myeloid progenitors. These immature leukemic cells accumulate in the bone 
marrow, blood and organs when the disease progresses and affect normal blood cell 
production resulting in leucocytosis and bone marrow failure (Grove & Vassiliou, 
2014). Common symptoms of AML are fatigue, anorexia and weight loss. Patients 
diagnosed with AML would die within weeks of infections or bleeding if not treated. 
 
1.1.3 Pathogenesis and classification of AML 
AML is a heterogeneous disease and most genomes from AML patients contain a 
series of mutations acquired over time (Grove & Vassiliou, 2014). This explains why 
the cytogenetic and mutational AML profile in older adults differs from that of 
younger patients (Rao et al., 2009). Even though AML appears mainly as de novo 
malignancy in previously healthy patients, it can also occur in patients as a result of 
prior therapy or in patients with an underlying haematological disorder (Sill, Olipitz, 
Zebisch, Schulz, & Wolfler, 2011). In 97% of AML cases at least one somatic 
alteration is identified (Patel et al., 2012) but structural abnormalities are absent in 
many cases and nearly 50% of the patients have a normal karyotype (Cancer Genome 
Atlas Research et al., 2013).  
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To explain how the different genetic events associated with AML lead to similar 
phenotypes, a two-hit model for leukaemogenesis is proposed (Kelly & Gilliland, 
2002). This model suggests that AML occurs as a consequence of a collaboration of 
two broad classes of mutations: class I and class II (Gilliland & Griffin, 2002). Class 
I mutations cause the activation of signal transduction pathways that lead to 
uncontrolled cellular proliferation and/or confer survival advantage to cells. Examples 
of such mutations include the tyrosine kinases FLT3 and c-KIT, N/KRAS and TP53. 
Class II mutations affect transcription factors and impair normal haematopoietic 
differentiation. Fusion transcripts such as RUNX1/ETO, CBFβ/MYH11 and 
PML/RARα, which are generated by recurring chromosomal aberrations (t(8; 21), 
inv(16) and t(15; 17)), all fall into this category (Gilliland & Griffin, 2002; Kelly & 
Gilliland, 2002; Speck & Gilliland, 2002; Takahashi, 2011) . Whilst the two-hit model 
is supported by the observation that one mutation on its own does not lead to AML 
development, it has been suggested that the model is an oversimplification due to the 
fact that other mutations, which do not fall into these categories, may play an important 
role in the pathogenesis of the disease. This has been supported by data from AML 
patients carrying additional mutations that modify the epigenetic status (Abdel-Wahab 
& Levine, 2013; Shih, Abdel-Wahab, Patel, & Levine, 2012). Mutations in genes that 
are involved in the epigenetic regulation of the genome such as TET2, IDH1/2, EZH2 
can cause changes in DNA methylation and histone modification and have been found 
in a significant portion of AML patients. Based on these recent findings a revised 
model of leukaemogenesis has been proposed, categorizing mutations into class I, 
class II and a further two classes of epigenetic modifier genes (Shih et al., 2012).   
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Figure 1.2 Revised model of leukaemogenesis 
AML is the consequence of a series of mutations affecting cell proliferation, survival and 
differentiation. Mutations contributing to the development of the disease have previously 
been categorized into class I and class II mutations. Mutations modifying the epigenetic 
status have recently been found in patients with myeloid malignancies. The above Circos 
diagrams shows the co-occurrence of mutations in AML patients suggesting to classify 
the mutations as class I, class II and two classes of epigenetic modifier genes.  
Reprinted by permission from Springer Nature [Nature Reviews Cancer, The role of 
mutations in epigenetic regulators in myeloid malignancies, (Shih et al., 2012)] 
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Knowing the underlying genetic alterations that lead to the development of AML and 
further defining the subtypes, helps us to better understand the disease and allows the 
use of targeted treatments based on the individual subtype characteristics.  
Established in 1976, the French-American-British (FAB) classification system first 
attempted to distinguish between different types of AML by defining eight subtypes 
(M0-M7) based on cyto-chemical characteristics and the morphology of the leukaemic 
cells (Bennett et al., 1976). The World Health Organization (WHO) introduced a new 
classification system in 2001 that has been revised twice, last time in 2016. In 
comparison to the FAB classification system, the WHO incorporated genetic 
information and distinguished AML into six major categories: AML with recurrent 
genetic abnormalities, AML with myelodysplasia-related features, therapy-related 
AML, AML not otherwise specified, myeloid sarcoma, and myeloid proliferation 
related to Down syndrome (Arber et al., 2016). Further subtypes of these categories as 
well as genetic abnormalities can be found in Table 1.1.  
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Table 1.1 World Health Organization Classification of AML 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
APL with PML-RARA 
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
AML with t(6;9)(p23;q34.1);DEK-NUP214 
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
Provisional entity: AML with BCR-ABL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
AML, NOS 
AML with minimal differentiation  
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis (TAM)  
Myeloid leukaemia associated with Down syndrome 
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1.1.4 AML Epidemiology 
AML is the most common acute leukaemia in adults and is responsible for 15-20% of 
the cases in children (O'Donnell et al., 2012). Even though it is estimated that there 
will be 19,520 new cases of AML in 2018 in the US, the disease is relatively rare. 
Based on SEER data from 2011-2015 cases, the National Cancer Institute reported that 
there were 4.3 new cases of AML per 100,000 men and women and 2.8 deaths per 
100,000 men and women per year (https://seer.cancer.gov/statfacts/html/amyl.html). 
The disease is most commonly found in older individuals (> 60 years) and the 
incidence generally increases with age from ~1.3 to 12.2 cases per 100,000 men and 
women comparing patients less than 65 years in age with those over 65 years (De 
Kouchkovsky & Abdul-Hay, 2016). AML is also more common in men than women 
and the number of new cases and deaths is not only dependent on age and sex but also 
on race/ethnicity. Whilst Caucasians have the highest percentage of new cases and 
deaths, Native Americans / Alaska Natives have the lowest incidence as reported by 
the National Cancer Institute.  
 
1.1.5 Treatment and Prognosis for AML 
Even though an improved survival rate has been reported over the past years with a 
current 5-year survival rate of ~ 27%, the prognosis of AML in older patients is still 
poor due to comorbidities, a reduced treatment response and treatment-related 
suffering (Dohner et al., 2010). Stratifying patients according to prognostic factors 
helps to decide which treatment is most beneficial for the patient (De Kouchkovsky & 
Abdul-Hay, 2016). Although clinical factors play an important role in therapy-related 
decisions, cytogenetic changes are the strongest prognostic indicator for overall 
survival and remission rates. Based on the cytogenetic changes, cases of AML can be 
divided into three prognostic risk groups: favourable, intermediate or adverse (Mrozek 
et al., 2012). Patients that fall into the favourable and intermediate prognostic risk 
group are treated according to the ‘7+3’ regime (‘10+3’ in the UK), which combines 
10 
 
7 days (10 days) of cytarabine treatment (100-200 mg/m2 daily) with 3 days of 
anthracycline (O'Donnell et al., 2017).  
Daunorubicin is the most commonly used anthracycline and is given at doses of 45-60 
mg/m2 daily. Using this standard for induction therapy to treat patients aged 50 years 
or younger shows a complete response rate between 60% and 80% (De Kouchkovsky 
& Abdul-Hay, 2016). Unfortunately, these rates are not observed in older patients or 
patients that fall into the adverse prognostic risk group. Intensive chemotherapy has 
not proven to increase the overall survival in elderly patients and early mortality as 
well as short-lasting responses are often the consequences of a less intensive therapy 
in those patients (Kantarjian et al., 2006). As a post-remission therapy, repetitive 
cycles of high-dose cytarabine are used in favourable- and intermediate risk AML. 
Alternatively, allogenic haematopoietic stem cell transplantation (HSCT) is a good 
post-remission option for patients with intermediate risk cytogenetics. HSCT is also 
recommended for elderly patients as well as patients with high risk cytogenetics 
(Almeida & Ramos, 2016).  
 
 
1.2 Protein tyrosine kinases 
Protein kinases represent one of the largest protein families in humans containing 538 
members that constitute about 1.7% of all human genes (Bhullar et al., 2018). Protein 
kinases regulate other proteins by post-translational phosphorylation of serine, 
threonine and tyrosine residues (Manning, Plowman, Hunter, & Sudarsanam, 2002).  
 
Protein tyrosine kinases (PTKs) were first discovered in 1979 (Eckhart, Hutchinson, 
& Hunter, 1979) and play a role in cell fate decisions through their involvement in cell 
differentiation, proliferation, survival and motility pathways (Hubbard & Till, 2000). 
PTKs themselves are controlled by post-translational modifications, such as 
phosphorylation and ubiquitination, and by changes in their abundance (Blume-Jensen 
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& Hunter, 2001). PTKs can be divided into receptor tyrosine kinases (RTKs) and non-
receptor tyrosine kinases (NRTKs). 
Whilst RTKs are transmembrane proteins consisting of an extracellular and 
intracellular domain, non-receptor tyrosine kinases do not have a transmembrane 
domain and are generally found in the nucleus, cytosol and inner surface of the plasma 
membrane (Krause & Van Etten, 2005). Non-receptor tyrosine kinases can be divided 
into 10 subfamilies with the SRC family being the largest (Figure 1.3).  
 
 
 
Figure 1.3 Non-receptor tyrosine kinase subfamilies 
The figure depicts the 10 subfamilies (left) of non-receptor tyrosine kinases indicating 
their domain structure and members listed on the right. 
Adapted from [Nature, Oncogenic kinase signalling, (Blume-Jensen & Hunter, 2001)] 
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1.2.1 TEC protein family of non-receptor tyrosine kinases 
The TEC family is the second largest non-receptor protein tyrosine kinase (NRTK) 
family and consists of 5 members: bone marrow-expressed kinase (BMX), Bruton’s 
tyrosine kinase (BTK), IL2-inducible T-cell kinase (ITK), tyrosine kinase expressed 
in hepatocellular carcinoma (TEC) and TXK. Unlike other NRTKs, TEC family 
kinases contain a pleckstrin homology domain and a conserved TEC homology 
domain that contains a Btk motif and a proline-rich region (Figure 1.3) (Tsukada et al., 
1993). The Btk motif contains a His and three Cys residues that form a zinc finger 
whilst the proline-rich region is involved in protein-protein interactions. Besides being 
involved in the activation of phospholipase-C γ and Ca2+ mobilization it has been 
shown that TEC family kinases also play a role in multiple signalling pathways 
including cell adhesion, actin remodelling and transcriptional regulation (Figure 1.4) 
(Fluckiger et al., 1998; Lin & Weiss, 2001).  
 
Mutations in TEC family kinases that lead to a loss-of-function mainly affect the 
haematopoietic system but also the liver and endothelial cells (Hussain et al., 2011; C. 
I. Smith et al., 2001). 
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1.3.2 Bruton’s tyrosine kinase (BTK) 
BTK was the third member of TEC family kinases identified and revealed the 
importance of the family with the discovery that the human disease X-linked 
agammaglobulinemia (XLA) was caused by mutations in BTK. Due to BTK’s 
involvement in the disease it was named after Ogden Bruton who reported the first 
case of XLA (Ponader & Burger, 2014). Of all tyrosine kinases in humans, BTK is the 
kinase for which most mutations have been identified (Hussain et al., 2011). The 
database documenting mutations in the BTK gene contains over 1700 entries with over 
800 unique DNA variants reported (https://databases.lovd.nl/shared/genes/BTK).  
 
Figure 1.4 Signals transmitted through TEC family Kinases 
TEC kinases are activated by membrane receptors such as GPCR, TNF and Cytokine 
receptors and are involved in different downstream pathways including apoptosis, 
adhesion and actin remodelling. 
Adapted from [Critical Reviews in Clinical Laboratory Sciences, Non-receptor protein 
tyrosine kinases signaling pathways in normal and cancer cells, (Gocek, Moulas, & 
Studzinski, 2014)] 
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1.2.3 BTK structure and regulation 
BTK is located on the X chromosome (Xq22.1) and is a 659 amino-acid protein 
containing 5 signalling domains (Figure 1.5). The amino-terminal pleckstrin homology 
(PH) domain is required for membrane localization. Unlike other non-receptor tyrosine 
kinases, BTK is mainly found in the cytoplasm and is only transiently recruited to the 
membrane (Hendriks, Yuvaraj, & Kil, 2014). The PH domain is followed by a proline-
rich TEC homology (TH) domain, which contains a highly conserved zinc-finger motif 
required for optimal activity and stability (Hyvonen & Saraste, 1997). BTK also 
contains the SRC homology domains SH3 and SH2, as well as a catalytic domain. SH3 
and SH2 have binding functions and SH3 contains the autophosphorylation site 
tyrosine Y223 whilst the primary phosphorylation site, Y551, is located within the 
catalytic domain (Mohamed, Nore, Christensson, & Smith, 1999). 
 
 
 
 
 
Figure 1.5 Domain structure of BTK 
Schematic domain structure or BTK. PH, Pleckstrin homology domain; TH, TEC 
homology domain; SH3 and SH2, Src homology domains. Following phosphorylation by 
Src kinases on Y551 the protein undergoes autophosphorylation at Y223. 
Adapted from [Journal of Clinical Oncology, Bruton's Tyrosine Kinase: From X-Linked 
Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies, (Ponader & 
Burger, 2014)] 
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BTK is activated by SRC and SYK family kinases following stimulation of cell surface 
receptors including growth factor and cytokine receptors, G protein-coupled receptors, 
integrins and antigen receptors (Ponader & Burger, 2014). After BTK is recruited to 
the plasma membrane by phosphatidylinositol (3,4,5)-trisphosphate (PIP3) via its PH 
domain it can undergo activating phosphorylation at Y551 by  SYK and LYN 
(Rawlings et al., 1996). This results in autophosphorylation at Y223 within the SH3 
domain (Park et al., 1996). BTK is expressed in all haematopoietic cells except T-cells 
and although it is mainly found in the cytoplasm a small proportion is also detected in 
the nucleus (Gustafsson et al., 2012). BTK is involved in many major pathways 
including phospholipase-C (PLC), nuclear factor kappa B (NF-κB), protein kinase C 
and phosphoinositol-3 kinase (PI3K)-AKT pathway (Lindvall et al., 2005).  
 
1.2.4 The role of BTK in AML 
Whilst BTKs role in B-cells is well studied and has been linked to several B-cell 
malignancies including Chronic Lymphocytic Leukaemia (CLL), Mantle Cell 
Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL) (D'Cruz & Uckun, 
2013), little is known about BTKs role in myelopoiesis. BTK inhibition/deficiency 
affects collagen-induced platelet aggregation (Quek, Bolen, & Watson, 1998), 
neutrophil development (Fiedler et al., 2011), macrophage lipopolysaccharide/TLR-
induced tumour necrosis factor (TNF) production (Horwood et al., 2006) and dendritic 
cell function via interleukin (IL)-10 and Stat3 (Kawakami et al., 2006). BTK mutations 
are absent in AML (Ritis et al., 1998) and BTKs role in the disease is not fully 
understood yet but its relevance has been reported quite recently. Several groups have 
studied the role of BTK in AML and it has been found that BTK protein expression 
levels are elevated in newly diagnosed patients compared to patients in complete 
remission (Tao et al., 2013) and that BTK promotes AML cell proliferation and 
survival via pathways downstream of Toll-like receptor 9 (TLR9) and FLT3-ITD in 
FLT3-ITD negative and FLT3-ITD positive cells respectively (Oellerich et al., 2015). 
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Furthermore, pharmacological inhibition of BTK using ibrutinib (a covalent BTK 
inhibitor) leads to reduced AML blast adhesion to bone marrow stromal cells and 
inhibits SDF1/CXCR4-mediated AML migration (Rushworth et al., 2014). Therefore, 
pharmacological inhibition of BTK may not only have a direct anti-proliferative effect 
but may also disrupt the protection of AML cells by the bone marrow 
microenvironment. These findings suggest a role for BTK as a therapeutic target in 
AML, however, further studies are needed to better understand the signalling pathways 
of BTK in myeloid cells and its mechanism of activation in AML.  
 
 
1.3 Ibrutinib  
1.3.1 Targeting protein tyrosine kinases in cancer 
Given the involvement of tyrosine kinases (TKs) in multiple pathways that control 
fundamental cellular functions it is not surprising that TKs have been found to be 
dysregulated in cancer cells. Out of the 90 TKs identified, 90% have been implicated 
in oncogenesis (Wilson et al., 2018). Genetically altered but also wild type TKs can 
act as “drivers” through different mechanisms including DNA-translocations, 
activating mutations and DNA amplifications (Figure 1.6). This generally results in 
constitutively active kinases that contribute to pathway signalling resulting in 
increased tumour cell proliferation and survival. 
 
The involvement of TKs in carcinogenesis explains why they are such attractive 
druggable targets in cancer therapy. By designing drugs to bind to the ATP or substrate 
binding domain of TKs, their catalytic activity can be inhibited. Drugs have also been 
designed to block dimerization of RTKs preventing ligand binding and receptor 
internalization. One of the most successful developed TK inhibitors is Imatinib which 
inhibits BCR-ABL TK activity, a fusion protein that is present in almost all chronic 
myelogenous leukaemia (CML) patients and 15% to 30% of adult acute lymphoblastic 
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leukaemia (ALL) patients but absent in normal blood cells (Faderl et al., 1999; 
Shawver, Slamon, & Ullrich, 2002). The development of Imatinib has increased the 
survival rate of CML patients in chronic and accelerated phase (Kantarjian et al., 2012) 
and demonstrated that targeting TKs is a promising approach in cancer therapy.  
Figure 1.6 Tyrosine Kinase activation in cancer 
Mechanisms of wild type and mutated tyrosine kinase activation together with 
compounds that have been developed to inhibit their activation. Mechanisms include 
genetical alterations (A-C) or pathway activations (D-F) that all contribute to increased 
tumour cell proliferation and survival.  
Reprinted by Permission from American Society of Microbiology [Molecular and 
Cellular Biology, Clinical Targeting of Mutated and Wild-Type Protein Tyrosine 
Kinases in Cancer, (Drake, Lee & Witte, 2014)] 
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1.3.2 Ibrutinib - a BTK inhibitor 
Ibrutinib is a first-in-class, oral, irreversible inhibitor of the TEC family kinase BTK. 
It belongs to a class of drugs called ‘targeted covalent drugs’ and is indicated for the 
treatment of adult patients with Mantle cell lymphoma (MCL), who have at least 
received one prior therapy, Chronic lymphocytic leukaemia (CLL) / Small 
lymphocytic leukaemia (SLL), CLL and SLL with 17p deletion, Waldenström’s 
macroglobulinemia (WM), Marginal zone lymphoma (MZL) who require systemic 
therapy and have received at least one prior anti-CD20-based therapy and Chronic 
graft versus host disease (cGVHD) after failure of one or more lines of systemic 
therapy (JanssenMD®). Ibrutinib inactivates BTK by binding to Cysteine 481 in the 
ATP binding pocket of the protein (Pan et al., 2007). Despite being highly selective 
for BTK (IC50 0.381 nmol/L) it also binds to other kinases with equivalent cysteine 
residues in the ATP binding pocket such as BLK, BMX, ErbB2, EGFR, JAK3, ITK 
and TEC (Singh, Petter, & Kluge, 2010). Comparing ibrutinib’s activity against those 
off-target effects, IC50 values for the same kinase found in the literature seem to differ 
but a high activity is observed against BLK (IC50 0.5 nmol/L), BMX (IC50 0.8 nmol/L), 
EGFR (IC50 1.81 nmol/L), ErbB2 (IC50 9.4 nmol/L) and ITK (IC50 10.7 nmol/L) (Bose, 
Gandhi, & Keating, 2016; Chen, Kinoshita, Sukbuntherng, Chang, & Elias, 2016). 
Whilst off-target binding can offer a therapeutic benefit in other diseases, it can also 
add a limitation due to off-target toxicity such as atrial fibrillation and bleeding 
observed for ibrutinib (Caldeira et al., 2019; Dreyling et al., 2016).  
 
 
1.3.3 Clinical effects of ibrutinib in B-cell malignancies 
Ibrutinib has demonstrated to benefit the duration and quality of life of patients with 
B cell malignancies. It took only 4.5 years from the clinical development and first in-
human treatment to the first regulatory approval in 2013 (Gayko et al., 2015).  
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In a study of CLL patients comparing Ofatumumab, an anti-CD20 antibody that 
inhibits early stage B lymphocyte activation, with ibrutinib, ibrutinib displayed a 78% 
lower progression risk and 57% lower death risk in previously treated patients (Byrd 
et al., 2014). In previously untreated patients aged 65 years and older, ibrutinib even 
achieved an overall response rate of 84% and an overall survival rate of 97% at 30 
months (Byrd et al., 2015).  
 
In a phase 1/2 clinical trial of patients with the diffuse large B cell lymphoma (DLBCL) 
subtype activated B cell like (ABC), 37% of patients receiving ibrutinib treatment 
showed a complete or partial response whilst only 5% of patients with the germinal 
centre B cell like (GCB) subtype responded to the treatment (Wilson et al., 2015). As 
the current cure rate for the ABC subtype is worse than for the GCB subtype, new 
ABC subtype specific treatment strategies are very important. Patients with the ABC 
subtype have chronic active B cell receptor signalling which therefore makes targeting 
the BCR signalling with ibrutinib a promising treatment strategy (Shaffer, Young, & 
Staudt, 2012). 
 
Ibrutinib has also shown good clinical effects in previously treated patients with 
Waldenström’s Macroglobulinemia. An overall response rate of 90.5% was 
determined with an estimated 2-year overall survival rate of 95.2%. Ibrutinib showed 
the highest efficacy in patients with MYD88L265P CXCR4WT (100% overall response 
rate) and the lowest efficacy in patients with MYD88WT CXCR4WT (71.4%) (Treon et 
al., 2015).  
 
Similar good outcomes were observed in a phase II clinical trial in patients with 
relapsed/refractory Mantle cell lymphoma (MCL). Ibrutinib demonstrated a 67% 
overall response rate at 24 months and a complete remission of 23% (M. L. Wang et 
al., 2015).  
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1.3.4 Targeting BTK beyond B-cell malignancies 
BTK is expressed in all haematopoietic cells except T-cells but as mutations in BTK 
do not seem to affect the myeloid phenotype or myeloid cell activity it was long 
assumed that BTK is not important for the development and function of these cells. 
This assumption was proven to be wrong when several groups demonstrated the 
importance of BTK in normal as well as malignant myeloid cells.  
BTKs role in myeloid cells as well as the increasing knowledge of ibrutinib’s off-target 
effects has led to the exploration of targeting BTK beyond B-cell malignancies 
including non-haematological malignancies.  
 
One example is the targeting of BTK in Multiple myeloma (MM). MM develops when 
malignant plasma cells accumulate in the bone marrow (BM). Overactive osteoclasts 
(OCs) and inactive osteoblasts (OBs) result in bone resorption and minimal bone 
regeneration, a clinical key feature of the disease (Raje & Roodman, 2011). BTK was 
identified to play a role in osteoclast (OC) differentiation (Shinohara et al., 2008) and 
was found to be expressed in cell lines and >85% of malignant plasma cells in Multiple 
myeloma (MM) patients (Rushworth et al., 2013; Tai et al., 2012). BTK inhibition 
using ibrutinib resulted in decreased bone resorption, decreased SDF-1-induced 
migration of MM cells and it also blocked MM cell growth and survival in vitro. In 
mice, ibrutinib inhibits MM cell growth and MM-induced osteolysis (Tai et al., 2012). 
These findings provided the preclinical results for clinical evaluation of ibrutinib as a 
therapeutic in MM.  
 
Ibrutinib activity has also been studied in several other tumour types including lung, 
breast, gastro-oesophageal, pancreatic, ovarian, prostata, glioma and renal cell 
carcinomas (Campbell, Chong, & Hawkes, 2018). Those studies led to the evaluation 
of ibrutinib in a phase I/II trial in patients with previously treated EGFR-mutant non-
small cell lung cancer (NSCLC) (Clinical Trials.gov ID NCT02321540), a phase II 
trial recruitment for MYC and/or HER2 amplified oesophageal cancer patients 
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(ClinicalTrials.gov ID NCT02884453), a phase II/III trial in patients with previously 
untreated metastatic pancreatic cancer (Tempero et al., 2016) (ClinicalTrials.gov ID 
NCT 02436668), a phase I/II study as initial curative treatment in men with prostate 
cancer undergoing prostatectomy (ClinicalTrials.gov ID 02643667) and a phase Ib/II 
trial in previously treated metastatic kidney cancer (ClinicalTrials.gov ID 
NCT02899078).  
Those studies show that a specifically targeted compound can be less restrictive than 
originally thought and that knowing off-target activities is useful for finding new 
indications and broadening the clinical application of the drug.  
 
1.3.5 Resistance mechanisms for the BTK inhibitor ibrutinib 
Ibrutinib has been approved by the US Food and Drug Administration (FDA) for the 
treatment of several diseases including CLL and MCL and has shown clinical 
effectiveness and tolerability. However, it was found that some of the patients who 
received ibrutinib treatment had exhibited a primary resistance while others developed 
an acquired resistance to the drug.  
 
In phase I and II studies of CLL, 14 out of 246 patients (5.3%) have disease progression 
(Furman et al., 2014). RNA-Seq or whole-exome sequencing was performed on 7 of 
the patients and revealed a cysteine to serine mutation at residue 481 in BTK (C481S) 
in 6 of the patients and mutations in PLCγ2 (L845F, R665W, S707Y) in two of the 
patients (Cheng et al., 2015; Woyach et al., 2014). In another clinical trial of 308 
patients, acquired mutations of BTK or PLCγ2 were detected in 85% of relapsed CLL 
patients and mutations in samples before relapse were detected at a median of 9.3 
months before clinical relapse (Woyach et al., 2017). The BTK C481S mutation was 
also found in relapsed MCL patients but was not present in MCL patients with a 
primary ibrutinib resistance (Chiron et al., 2014). 
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The S707Y mutation in PLCγ2 has previously been characterized and was identified 
to have a gain-of-function effect by disrupting the autoinhibitory SH2 domain leading 
to enhanced PLCγ2 activity (Zhou et al., 2012). The L845F and R665W mutations in 
PLCγ2 are less characterized but in vitro models demonstrated that these mutants 
appear to bypass BTK upon BCR activation, as indicated by higher cytosolic Ca2+ 
levels (T. M. Liu et al., 2015).  
Functional analysis of the BTK C481S mutation revealed reversible binding of 
Ibrutinib to the protein together with a reduced binding affinity (Woyach et al., 2014). 
In addition to the C481S mutation other mutations within the protein have been 
identified including C481F/Y/R, T474I/S, T316A and L528W (Sharma et al., 2016). 
As some of these mutations are only present at 4-8% variant allele frequencies their 
effects have not yet been assessed (Maddocks et al., 2015). Even though BTK 
mutations are only present in patients who have received ibrutinib treatment, it is 
possible that these mutations are present at a low frequency in patients prior to therapy, 
expanding with the pressure of the drug (Komarova, Burger, & Wodarz, 2014). The 
cysteine to serine mutation in BTK (C481S) seems to be the most common mutation 
leading to ibrutinib resistance, but further investigation is required to understand the 
mechanisms behind the other identified mutations and whether they cause or coexist 
with ibrutinib resistance.  
 
1.3.6 Second generation BTK inhibitors 
Resistance to ibrutinib as well as the drugs off target effects have led to the 
development of more specific second generation BTK inhibitors such as ONO/GS-
4059, ACP-196 and GDC-0853. GDC-0853 is the most specific BTK inhibitor 
developed so far but ONO/GS-4059 and ACP-196 are also more potent than ibrutinib 
(Wu, Liu, Tsui, & Liu, 2016). Like ibrutinib, both ONO/GS-4059 and ACP-196 are 
irreversible inhibitors whilst GDC-0853 is a reversible, noncovalent inhibitor. 
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In comparison with ibrutinib, other more selective irreversible BTK inhibitors have 
the advantage of less off target effects, thereby reducing the side effects in patients. 
Studies with ibrutinib have shown that toxicities related to off target binding are 
common and can include gastrointestinal toxicity, haematological toxicity as well as 
bleeding.  
 
Clinical studies in different B-cell malignancy subsets with ONO/GS-4059 and ACP-
196 have shown a lower incidence of associated toxicities (Byrd et al., 2016; Walter 
et al., 2016) but due to a similar electrophilic warhead to ibrutinib, these compounds 
are likely not efficient in patients carrying Cys481 mutations. GDC-0853 on the other 
hand binds the hinge region of BTK but does not interact with the Cys481 residue and 
would be expected to obtain its activity against BTK C481S (Crawford et al., 2018). 
GDC-0853 is currently being used in a first-in-human Phase I study of patients with 
relapsed or refractory B-cell NHL and CLL that relapsed on ibrutinib, particularly 
those carrying the BTK C481S mutation (ClinicalTrials.gov Identifier: 
NCT01991184). Results of this study will show if GDC-0853 can overcome ibrutinib 
resistance.    
 
 
1.4 Genome editing 
1.4.1 Development and mechanism of targeted genome editing 
Genome editing describes the process of manipulating the DNA of a cell or organism. 
Genome editing technologies have advanced immensely over the past few years 
enabling researchers now to precisely modify a specific locus within the genome. 
Conventional gene targeting is achieved by providing cells with a donor DNA template 
containing a gene of interest or mutation that would recombine at a target site by 
homologous recombination (HR) (Capecchi, 1989, 2005).  
24 
 
This technique is utilised extensively to generate “knock-out” mice but unfortunately 
the levels of HR in most other cell types are orders of magnitude lower than the murine 
embryonic stem cells. 
 
The foundation for targeted genome editing was set with the discovery in 1988 that 
the poor efficiency of HR could be boosted in yeast by the introduction of double-
strand breaks (DSBs) and this was later demonstrated to also be applicable to 
mammalian cells (Figure 1.7) (Rouet, Smih, & Jasin, 1994; Rudin & Haber, 1988). 
 
Genome editing development was further boosted with the discovery that DSBs are 
repaired via non-homologous end joining (NHEJ) in the absence of a donor DNA 
template leading to a potential mechanism of gene disruption (Wake, Gudewicz, 
Porter, White, & Wilson, 1984).  
 
Zinc finger nucleases (ZFNs) were the first to be used to make precise genomic 
modifications followed by transcription activator-like effector nucleases (TALENs) 
and most recently clustered regularly interspaced short palindromic repeats (CRISPR) 
– associated Cas9 (CRISPR/Cas9). The nucleases and their individual characteristics 
Figure 1.7 Timeline of nuclease-dependent gene editing methods 
Timeline from 1988 to 2015 of landmark discoveries in the genome editing field.  
Adapted from [Nature Protocols, Genome editing comes of Age, (J. S. Kim, 2016)] 
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are described below in the next few sections. Regardless of their differences, all three 
systems use the same mechanism of action – targeted delivery of a nuclease leading to 
cleavage of DNA that triggers the cells natural repair mechanism resulting in specific 
genome modifications. 
 
A DSB is repaired through one of two major pathways: Non-homologous end joining 
(NHEJ) and Homology directed repair (HDR). NHEJ is an error-prone mechanism that 
religates the broken DNA directly, does not require a homologous template and is 
active throughout the cell cycle (Weterings & Chen, 2008). During NHEJ, the DSB is 
detected by the Ku 70/80 heterodimer which has a high affinity for DSBs (Walker, 
Corpina, & Goldberg, 2001) and consequently forms a complex with DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs) (Weterings, Verkaik, Bruggenwirth, 
Hoeijmakers, & van Gent, 2003). The exposed DNA termini are then processed by 
DNA polymerases µ and λ (Nick McElhinny et al., 2005) and the Ligase IV/X-Ray 
Cross-Complementation group 4 protein (XRCC4) complex ligates the DSB ends 
(Mahaney, Meek, & Lees-Miller, 2009).  
 
HDR, by comparison, is an error-free process that requires a homologous template and 
is only active in late S and G2 phases of the cell cycle (Kakarougkas & Jeggo, 2014). 
The MRN complex consisting of Mre11, Rad50 and NbsI detects the DSB and 
removes nucleotides to create 3’ DNA single stranded overhangs (Kobayashi, 
Antoccia, Tauchi, Matsuura, & Komatsu, 2004). The Rad51 family of proteins and 
other HR proteins are then recruited to the overhangs coated with replication protein 
A (RPA) and the overhangs invade the complementary sister chromatid. The single 
strand base pairs with the complementary strand, forms a D-Loop and DNA-
Polymerases extend the invading strand from the 3’ end. The cross-over structure 
formed is then reversed and the adjacent ends ligated by Ligase I completing the repair 
of the DSB (San Filippo, Sung, & Klein, 2008).  
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1.4.2 Zinc finger nucleases 
Zinc finger nucleases (ZNFs) are endonucleases containing a DNA-binding motif 
fused to a separate DNA-cleavage domain (Carroll, 2011). The binding domain, a class 
of eukaryotic transcription factors called zinc finger proteins (ZFPs), can be 
customized to target any user-defined sequence providing DNA binding specificity.  
The most common binding domain in humans is the Cys2His2 zinc finger (Chou, 
Leng, & Mixson, 2012) with each zinc finger domain recognizing around three base 
pairs of DNA (Pavletich & Pabo, 1991). The cleavage domain is non-specific and is 
mediated by the restriction enzyme FokI (Bibikova et al., 2001; J. Smith et al., 2000). 
FokI is only active as a dimer, therefore two sets of fingers must bind to neighbouring 
sequences on opposite strands to enable the FokI to dimerize and cleave the DNA 
(Figure 1.8). The requirement of dimerization has two advantages; the first is that 
binding of a single ZNF does not lead to cleavage because the monomer is not active. 
The second advantage is that two ZNFs provide a higher target specificity therefore 
reducing off-target cleavage as they have to bind within a certain distance from one 
another to enable the FokI to dimerize.  
Figure 1.8 Structure and design of Zinc finger nucleases 
a Zinc finger nuclease dimer bound to its target with each ZFP containing a FokI 
cleavage domain and an array of zinc fingers that recognize the target site flanking the 
cleavage site. b An example of a three finger protein with specificity for the sequence 
GGGGGTGAC.  
Reprinted by Permission from Springer Nature [Nature Reviews genetics, Genome 
editing with engineered zinc finger nucleases, (Urnov, Rebar, Holmes, Zhang, & 
Gregory, 2010)] 
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ZNF pairs have been developed and successfully been used in a variety of organisms 
and cell types including Drosophila, Zebrafish, Rat, Mouse, Human, Tobacco and 
Maize (Carroll, 2011).  
 
 
1.4.3 Transcription activator-like effector nucleases 
Transcription activator-like effector nucleases (TALENs) are similar to ZFNs, 
containing two user-defined DNA binding domains linked to the FokI endonuclease 
domain (Figure 1.9) (Joung & Sander, 2013). The DNA binding domains, TALEs, are 
repeats of 33-35 amino acids each that recognize a single nucleotide in the target 
sequence (Pellagatti, Dolatshad, Yip, Valletta, & Boultwood, 2016). TALEs are 
proteins found in the protobacteria of the Xanthomonas species (Boch & Bonas, 2010). 
Within each alpha-sheet repeat there are two amino acids at positions 12 and 13 known 
as repeat variable diresidues (RVDs) (Boch et al., 2009) that can be modified to target 
a specific base. The four RVDs; NI (Asn-Ile) , NN (Asn-Asn), HD (His-Asp) and NG 
(Asn-Gly) are most widely used and recognize the DNA nucleotides A, G, C and T 
respectively (Deng et al., 2012). One advantage of TALENs over other nucleases is 
that almost any DNA sequence can be targeted, and the simple protein-DNA 
recognition code makes it easy to design TALENs. Construction and delivery into cells 
however can be challenging due to the large size of TALENs that can often consist of 
up to 20 almost identical RVD-containing motifs, precluding them for use in viral 
delivery methods. 
 
Despite this TALENs have successfully been used in a variety of species including 
plants, frogs, fish, mice and mammalian cells (H. Kim & Kim, 2014).  
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1.4.4 Clustered regularly interspaced short palindromic repeats 
The most recently developed programmable nuclease is the CRISPR/Cas9 
endonuclease. CRISPR is a natural system used by bacteria and archaea to protect 
themselves from infections by viruses and invading plasmids (Wiedenheft, Sternberg, 
& Doudna, 2012). The CRISPR/Cas systems can be divided into two classes with each 
class including 3 types and several subtypes. Class 2 systems (type II, V, VI) act as 
monomers whilst Class 1 systems (type I, III, IV) act as multi subunit effector 
complexes. Type I, II and V systems target DNA whilst the type VI system targets 
RNA and the type III system can target both (Koonin, Makarova, & Zhang, 2017). The 
most commonly used Cas enzyme in genome editing is SpCas9 derived from 
Streptococcus pyogenes which belongs to the Class 2, type II system. 
 
 
 
Figure 1.9 Schematic diagram of a TALEN pair 
A schematic of a TALEN pair with each composed of TALE repeats and a Fok I 
domain. Each TALE recognizes a single base through the amino acids at position 12 
and 13 (RVD, shown in red). 
Reprinted by Permission from Springer Nature [Nature Reviews Genetics, A Guide to 
genome engineering with programmable nucleases, (H.Kim & Kim, 2014)] 
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The Cas9 endonuclease contains a RuvC and HNH nuclease domain responsible for 
cleavage of the non-complimentary and complimentary strand, respectively (Figure 
1.10) (Sternberg, LaFrance, Kaplan, & Doudna, 2015). Unlike ZNFs and TALENs that 
contain a modifiable DNA-binding domain, CRISPR/Cas9 can target a user-defined 
sequence by replacing guide RNAs making it easily re-taskable (J. S. Kim, 2016). As 
well as Cas9, two other components are required: the CRISPR RNA (crRNA) and the 
trans-activating crRNA (tracrRNA) (Deltcheva et al., 2011). The crRNA, also known 
as protospacer, is the sequence that can be modified to target a specific location within 
the genome. The tracrRNA hybridizes with the crRNA and provides a scaffold for 
Cas9 binding (Pellagatti et al., 2016). It was discovered that the tracrRNA and crRNA 
can be fused together to create a single guide RNA (sgRNA) simplifying its use in 
plasmid-based delivery systems (Jinek et al., 2012). 
Figure 1.10 CRISPR/Cas9 System 
The Cas9 nuclease is recruited to the DNA by the tracrRNA:crRNA (trans-activating 
crRNA:CRISPR RNA) duplex and after binding upstream of the PAM (Protospacer 
adjacent motif) sequence a double strand break is induced by the RuvC and HNH 
domain. 
Adapted from the Cell culture dish [CRISPR/Cas9 system and its applications, Debbie 
King] 
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The Cas9 endonuclease also requires a species-dependent Protospacer Adjacent Motif 
(PAM) for DNA binding immediately 3’ to the target sequence which can limit guide 
placement depending on the genomic location. The PAM site of SpCas9 5’ NGG 
occurs approximately every 8 bps (Graham & Root, 2015), which is frequent enough 
for gene knock-out/knock-ins but can be a limitation for targeting specific nucleotides. 
Recognition of the PAM by Cas9 triggers a conformational transformation and enables 
cleavage of the DNA (Sternberg, Redding, Jinek, Greene, & Doudna, 2014).  
 
The induced DSB is then repaired via NHEJ or HDR, as described previously, 
resulting in sequence insertions, nucleotide changes or corrections via the HDR 
pathway, in the presence of a suitable homologous template, or small insertions and 
deletions (indels) via the NHEJ pathway (Figure 1.11).  
 
Figure 1.11 Double strand break repair promotes gene editing 
A Cas9 induced DSB is repaired via the error prone NHEJ pathway resulting in random 
small insertions and deletions or via HDR in the presence of a suitable repair template 
allowing precise gene editing.  
Reprinted by Permission from Springer nature [Nature protocols, Genome 
engineering using the CRISPR-Cas9 system, Ran et al., 2013] 
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Several Cas9 variants and orthologues have been identified, characterized and adapted 
for genome editing. As different orthologues recognize different PAM sites and require 
a different lengths of target sequence, their use can overcome the SpCas9 PAM 
limitation and widen the range of available sequences that can be targeted (Cebrian-
Serrano & Davies, 2017). Two Cas9 orthologues (SaCas9 and AsCas12a) and their 
characteristics are described below.  
 
SaCas9 belongs, like SpCas9, to the Class 2 type II CRISPR system but is derived 
from Staphylococcus aureus. SaCas9 targets sequences of 21 to 24 bps and requires a 
5’ NNGRRT PAM for DNA binding. One advantage of SaCas9 over SpCas9 is its 
smaller size (1053 vs 1368 amino acids) which allows packaging into adeno-associated 
virus vectors and therefore makes delivery, especially in vivo, much easier (Ran et al., 
2015). 
 
Another Cas9 orthologue from Acidaminococcus sp., AsCas12a, belongs to the class 
2 type V CRISPR systems and has unique features distinct to SpCas9 (Jeon et al., 
2018). Unlike SpCas9, AsCas12a only requires a crRNA and has the ability to process 
its own pre-crRNA into crRNA allowing multiplex genome editing (Fonfara, Richter, 
Bratovic, Le Rhun, & Charpentier, 2016; Zetsche et al., 2017). Furthermore, AsCas12a 
creates a DSB by inducing a staggered cut downstream of the PAM site 5’ TTN 
containing only a single active site in the RuvC domain and missing the HNH nuclease 
domain (Yamano et al., 2016).  
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1.4.5 Applications of the CRISPR/Cas system in cancer biology 
Genome editing technologies have nearly endless applications from basic biology to 
biotechnology and medicine. In 2015, a one year old girl with leukaemia was 
successfully treated with CAR T-cells, generated using TALENs (Reardon, 2015). 
Another in human application of targeted nucleases (ZNFs) was used to disrupt CCR5 
gene expression, a receptor used by most HIV strains to enter and infect cells (Wang 
& Cannon, 2016). Since then, targeted nucleases have been used to better understand 
molecular mechanisms of several diseases, including cancer, and genome editing has 
been applied to multiple stages of drug discovery and development.  
 
The CRISPR/Cas system has not yet been used for in human applications but is a 
breakthrough in the study of cancer genes in mouse models. Tumour suppressor genes 
p53 and PTEN were successfully targeted in the liver using CRISPR/Cas9 allowing 
the development of liver cancer models and functional genomics (Xue et al., 2014). 
To study lung adenocarcinoma, loss of function mutations in p53 and Lkb1 as well as 
the KRASG12D mutation were generated using CRISPR/Cas9, leading to the formation 
of tumours with adenocarcinoma pathology (Platt et al., 2014). Chromosomal 
rearrangements are common in the pathogenesis of human cancers but have proven to 
be challenging to model in mice. The CRISPR/Cas system can effectively model 
chromosomal rearrangements such as inversions and duplications. The Eml4-Alk 
inversion expressing the Eml4-Alk fusion gene was generated in a mouse model using 
CRISPR/Cas9 to study lung cancer (Maddalo et al., 2014). The list of applications of 
the CRISPR/Cas system in cancer biology is endless with its ability to target any gene 
and either inhibit, repress, activate, translocate, invert or duplicate them. Most 
importantly, the CRISPR/Cas system offers a replacement for nearly all long 
experimental procedures for cancer gene therapies (Sachdeva et al., 2015). Newly 
identified mutations in oncogenes and tumour suppressor genes can rapidly be 
modelled and functionally analysed and help to choose the optimal targeted therapy in 
individual cancer patients (Kannan & Ventura, 2015).  
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1.5 Thesis aims 
Manipulating the genome of normal and cancer cells is an important approach to model 
the disease and study the many genes that are involved in the pathogenesis. The 
CRISPR/Cas system is a rapidly evolving tool for genome editing allowing easy 
alteration of the genomes of a huge variety of organisms. This not only helps to better 
understand the cancer biology but also contributes to the development of novel anti-
cancer drugs and the study of drug resistance.  
 
Acute myeloid leukaemia (AML), a malignant disease of the bone marrow and blood, 
is associated with a poor prognosis in general. Despite an improved understanding of 
pathogenesis, AML treatment has changed little over the past years. Due to the 
heterogeneity of the disease, treatment response as well as drug resistance and disease 
relapse varies, and personalized therapeutic regimes pose a challenge.  
 
Our first aim was to establish and validate a CRISPR-based gene knock-out as well as 
knock-in strategy in HEK-293T cells targeting Bruton’s tyrosine kinase (BTK), a 
potential therapeutic target in AML.   
 
We next wanted to use CRISPR to generate the C481S mutation of BTK in the AML 
cell lines HL-60, MV4-11, U937, THP-1 and OCI-AML3. The C481S mutation causes 
secondary drug resistance in some patients treated with the BTK inhibitor ibrutinib. 
 
Our third aim was to study the functional consequences of the BTK C481S mutation 
in AML cell lines using ibrutinib. 
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Chapter 2: Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
2.1 Materials 
2.1.1 Purchased Reagents and Kits 
A list of reagents and kits used in this thesis can be found in Table 2.1. The majority 
of reagents were purchased from either Sigma-Aldrich (Poole, UK) or Thermo Fisher 
Scientific (Loughborough, UK). 
  
Table 2.1 Purchased Reagents and Kits 
Name Supplier 
4 x Laemmli Buffer Bio-Rad 
Acrylamide Geneflow 
Agarose Invitrogen 
Ammonium persulfate (APS) Thermo Fisher Scientific 
Annexin V APC Biolegend 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
DC Protein Assay kit Bio-Rad 
Dimethylsulphoxide (DMSO) Sigma-Aldrich 
DNA Ladder 100 bp / 1 kb NEB 
Dulbecco’s Modified Eagle’s Medium (DMEM) Invitrogen 
Ethidium bromide (EtBr) Promega 
Foetal bovine serum (FBS) Invitrogen 
GDC-0853 MedChemExpress 
Hexadimethrine bromide (polybrene) Sigma-Aldrich 
Hybond C Nitrocellulose membrane Amersham 
Ibrutinib Selleckchem 
Immobilon Western Chemiluminescent HRP 
substrate 
Millipore 
KiNET-1 CTx-0294885 SYNkinase 
Luria Bertani (LB)  Sigma-Aldrich 
Methylcellulose Sigma-Aldrich 
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Milk powder Tesco 
Mix and go E.Coli transformation kit Zymo Research 
Non-essential Amino Acids (NEAA) Invitrogen 
OneTaq Quick-Load 2 x Master Mix with Standard 
Buffer 
NEB 
Opti-MEM Invitrogen 
Penicillin, Streptomycin (10 mg/ mL) Invitrogen 
Phosphate buffered saline (PBS) Sigma-Aldrich 
PhosSTOPTM Phosphatase Inhibitor Roche 
Precision Plus Protein Kaleidoscope Prestained 
Protein Standard  
Bio-Rad 
Propidium Iodide (PI) Sigma-Aldrich 
Protease Inhibitor Cocktail Roche 
PureLinkTM HiPure Maxiprep Kit Invitrogen 
PureLinkTM Quick Plasmid miniprep Kit Invitrogen 
Puromycin Invivogen 
RNeasyTM mini kit Qiagen 
Roswell Park Memorial Institute (RPMI) Invitrogen 
SuperScript III Reverse Transcriptase Invitrogen 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
TransIT-mRNA Transfection Kit Mirus 
TransIT-Oligo Transfection Reagent Mirus 
Trypsin/EDTA (0.25%) Sigma-Aldrich 
Tween 20 Fisher Bio Reagents 
Wizard SVTM Gel and PCR Clean-Up System Promega 
β-Mercaptoethanol Sigma-Aldrich 
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2.1.2 Buffers 
 
Table 2.2 Buffers 
Name Constituents 
1 x Annexin V binding buffer  
 
10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 
2.5 mM CaCl2 
1 x TAE buffer 40 mM TRIS, 20 mM acetic acid and 1 mM 
EDTA 
10 x Running buffer 1% (w/v) SDS, 1.92 M glycine, 0.25 M Tris 
 
10 x TBS 10 mM Tris-HCl, 150 mM NaCl, pH 8.0 
 
10 x Transfer buffer 0.25 M Tris, 1.92 M glycine 
High salt MIB wash buffer 50 mM HEPES (pH 7.5), 1 M NaCl, 0.5% Triton 
X-100, 1 mM EDTA, 1 mM EGTA 
Low salt MIB wash buffer 50 mM HEPES (pH 7.5), 150 mM NaCl, 0.5% 
Triton X-100, 1 mM EDTA, 1 mM EGTA 
MIB elution buffer 0.5% (w/v) SDS, 1% (v/v) β-Mercaptoethanol, 
0.1 M Tris-HCl (pH 6.8), LC-MS grade water 
MIB lysis buffer 50 mM HEPES (pH 7.5), 150 mM NaCl, 0.5% 
Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 
mM NaF, 2.5 mM NaVO4 
Resolving gel buffer 1.5 M Tris-HCl, 0.4% (w/v) SDS, pH 8.8 
 
RIPA buffer 150 mM sodium chloride, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl 
sulfate, 50 mM Tris pH 8.0  
SDS wash buffer 0.1% (w/v) SDS in low salt MIB wash buffer 
Stacking gel buffer 0.5 M Tris-HCl, 0.4% (w/v) SDS, pH 6.8 
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Tail lysis buffer 
 
50 mM Tris/HCL (pH 7.5), 150 mM NaCl, 1 mM 
EDTA 
TBST 1 x TBS, 0.1% tween 20  
 
 
2.1.3 Antibodies 
All primary and secondary antibodies were purchased from Cell Signalling 
Technology. A table of antibodies used in this thesis is found in Table 2.3. 
 
Table 2.3 Primary and secondary antibodies 
Antibody Type Species MW (kDa) Dilution 
β-Actin Polyclonal Mouse  42 1:10000 
Cas-9 Monoclonal 
(7A9-3A3) 
Mouse 160 1:1500 
Btk Monoclonal 
(D3H5) 
Rabbit 77 1:1000 
p-Btk (Tyr223) Monoclonal 
(D9T6H) 
Rabbit 77 1:1000 
PLCγ2 Polyclonal Rabbit 150 1:1000 
p-PLCγ2 
(Tyr1217) 
Polyclonal Rabbit 150 1:1000 
Akt (pan) Monoclonal 
(40D4) 
Mouse 60 1:1000 
p-Akt (Ser473) Monoclonal 
(D9E) 
Rabbit 60 1:1000 
p42/44 MAPK Polyclonal Rabbit 42,44 1:1000 
p-p42/44 MAPK 
(Thr202/Tyr204) 
Monoclonal 
(197G2) 
Rabbit 42,44 1:1000 
Anti-rabbit IgG  Goat  1:3000 
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Anti–mouse IgG  Horse  1:5000 
 
 
2.1.4 Primers, guides and ssODN 
Primers and guide oligonucleotides were purchased from Integrated DNA 
technologies (IDT, Leuven, Belgium). Single-stranded oligodeoxynucleotides 
(ssODN) used as homology directed repair (HDR) template was purchased from 
Sigma. A full list of primers, guide oligonucleotides and the ssODN used in this thesis 
can be found below in Table 2.4.  
 
Table 2.4  Primers, guides and ssODN sequences 
Primers Sequence 5’ to 3’ 
  
ex15F ATCTATTTGCTGGAGTCTAGG 
Ex15F EcoRI AGGAATTCACACAACAACCCACT
GAGG 
ex15R AGGCTGGAGATATTTGATGGG 
Ex15R NheI GCAAACCCTTAAAAAGAAACATT
TCGCTTGCTAGCTCTAG 
ex15R2 CCACATTCTCACGAACCGCC 
ex2F GGAACCAAGAGGGATGAGG 
ex2R GGTAGTCATAGATTTATAGATC 
ex3F GCCCTCCATTTGGTAGTCATAG 
ex3R CCCTCAGTTCTCTCAGGATC 
mutF ATGGCGAACGGTAGTCTTC 
mutR TAAGAAGACTACCGTTCGC 
sgRNA reverse GGCACCGAGTCGGTGCTTTT 
T7-sgRNA forward TAATACGACTCACTATAGGGCTG
CCTCCTGAACTACC 
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Template R CCCATCTTCATCATCACTGAGTAC
AT 
  
SpCas9 guides Sequence 5’ to 3’ 
  
Guide #1 (exon 15) CCTGAACTACCTGAGGGAGAT 
Guide #2 (exon 15) ATGGCTGCCTCCTGAACTA 
Guide #3 (exon 15) CTGCCTCCTGAACTACCTG 
Guide #4 (exon 15) AGCAGCGCCCCATCTTCAT 
Guide #5 (exon 15) CTGCCTCCTGAACTACCTGA 
Guide #7 (exon 2) AGCTATGGCCGCAGTGATTC 
Guide #8 (exon 2) GTTTCTCTTGACCGTGCACA 
Guide #9 (exon 3) GATCACTTGTGTTGAAACAG 
Guide #10 (exon 3) GAAAGACAGATTCCGGTAAG 
  
SaCas9 guide Sequence 5’ to 3’ 
  
Guide #6 (exon 15) GCGCCCCATCTTCATCATCA 
  
Cas12a guides Sequence 5’ to 3’ 
  
Cas12a #1 (exon 2) ATTATCAACAGCACACAGGTGAA 
Cas12a #2 (exon 2) CAACAGCACACAGGTGAACTCCA 
Cas12a #3 (exon 2) TGAAGCGATCCCAACAGAAAAAG 
Cas12a #4 (exon 2) TCTTGACCGTGCACAAACTCTCCT 
  
HDR template Sequence 5’ to 3’ 
HDR template binding to bases 38 to 
148 within exon 15 of BTK (equal to 
bases 19154 to 19265 of the whole gene 
sequence) 
GTCTGCACCAAGCAGCGCCCCAT
CTTCATCATCACTGAGTACATGGC
GAACGGTAGTCTTCTTAATTATCT
TAGAGAGATGCGCCACCGCTTCC
AGACTCAGCAGCTGCTA 
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2.1.5 Plasmids 
Plasmids were purchased from Addgene or were a kind gift from Dr. Nicholas Harper. 
Plasmid maps can be found in the Appendix.  
 
Table 2.5 Plasmids 
Name Details 
LentiCRISPR v2 Lentiviral plasmid expressing SpCas9 
pCW-Cas9 Doxycycline-inducible SpCas9 
expressing lentiviral plasmid 
pLeGO EGFP expressing lentiviral plasmid 
pX459 Nonviral SpCas9 expressing plasmid 
pX601 Adeno-associated viral plasmid 
expressing SaCas9 
pcDNA6 Mammalian expression vector 
 
 
2.1.6 Cell lines 
All AML cell lines (HL-60, MV4-11, OCI-AML3, THP-1 and U937) were obtained 
from the American Type Culture Collection (ATCC). Cell identity was verified by the 
supplier via STR analysis. The human embryonic kidney cell line HEK-293T was a 
kind gift from Dr. John Quinn.  
 
2.2 Maintenance of cell lines 
2.2.1 Cell culture 
All cell lines were cultured in T75 tissue culture flasks at 37°C in a humidified 
atmosphere containing 5% CO2 and tested for mycoplasma contamination twice using 
PCR.  
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AML cell lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 
supplemented with 1% GlutaMax, 20% heat-inactivated foetal bovine serum (FBS) 
and 10 U/mL Penicillin/Streptomycin. 
 
HEK-293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), both 
supplemented with 10% FBS and 10 U/mL Penicillin/Streptomycin. 
 
All cells were passaged 2-3 times a week to maintain a density appropriate for each 
cell line. Suspension cells were diluted in their culture flask either by adding growth 
medium until the maximal culture volume was reached or by withdrawing a portion of 
cells and adding medium to the remaining cells.  
 
The adherent cell line HEK-293T had to be enzymatically treated to detach the cells 
from the culture flask surface prior to passaging. When cells were confluent, the 
growth medium was removed and 5 mL of trypsin ethylenediaminetetraacetic (EDTA) 
solution was added to the cells. After incubation for 5 min at 37°C / 5% CO2 an equal 
volume of growth medium was added to the cells to inactivate trypsin. Cells were then 
transferred to a 15 mL conical tube and pelleted at 113 x g for 3 min. The supernatant 
was removed, and cells were resuspended in 5 mL of growth medium. Part of the media 
containing cells was transferred to the culture flask and cells were further diluted with 
growth medium.  
 
2.2.2 Cryopreservation and Thawing cells 
For Cryopreservation cells were centrifuged at 113 x g for 5 min, growth medium was 
removed, and cells were resuspended in freezing medium consisting of 90% FBS and 
10% Dimethyl sulfoxide (DMSO). Cells were then transferred into 2 mL cryogenic 
vials and placed into a Mr. Frosty Freezing Container for storage at -80°C overnight. 
The freezing container is filled with isopropanol to allow the samples to achieve a slow 
cooling rate of -1°C / minute which is the optimal rate for cell preservation. Following 
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overnight storage, cryogenic vials were transferred into liquid nitrogen for long-term 
storage.  
To defrost cells, cryogenic vials were taken out of the liquid nitrogen tank and left at 
room temperature for several minutes to thaw. Warm cell culture medium was added, 
and cells transferred into a 15 mL conical tube for centrifugation at 113 x g for 5 min. 
Cells were then resuspended in 7 mL culture medium and placed into a T25 tissue 
culture flask.  
 
2.2.3 Single cell clone Isolation 
Single cell clones were isolated by growing cells in methylcellulose. 2.4 g of sterilised 
methylcellulose 1500 cP dry powder was added to 50 mL of sterile water and gently 
simmered for several hours with constant stirring. The solution was then cooled to 
50°C and diluted 1:1 with 2 x RPMI medium. To allow the methylcellulose to fully 
solubilise the solution was stirred overnight at 4°C. The following day the solution 
was transferred to a 50 mL conical tube and centrifuged at 920 x g for 60 min to clear 
any particles that had not solubilised. The methylcellulose solution was stored at -20°C 
in 10 mL aliquots until used.   
 
50 µL of non-essential amino acids (NEAA), 50 µL of 10 U/mL 
Penicillin/Streptomycin and 1 mL FBS were added to 2 mL of media containing 3000 
cells. 3 mL of Methylcellulose / RPMI was added to the cells and mixed with a 5 mL 
syringe and 12-gauge needle. This was then left to stand for the bubbles to disperse 
before the cells were seeded in either a 6 well or 12 well plate (2.5 mL / 1 mL). Plates 
were left for 10-14 days after which colonies were picked under a microscope using a 
10 µL pipette and transferred to a 96 well plate for expansion.  
 
2.2.4 Ibrutinib treatment and wash-out experiment 
1.5 x 106 THP-1 and OCI-AML3 wild type cells as well as selected BTKC481S positive 
clones were seeded in a 12 well plate in 1.5 mL of media. Cells were treated with 1, 3, 
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10, 30, 100, 300, 1000 nM ibrutinib for 2.5 h. Untreated cells and vehicle treated cells 
were used as a control. Cells were then either harvested or washed with PBS 3 times 
and incubated for another hour (wash out experiment).  
 
2.3 Protein analysis 
2.3.1 Protein Isolation and quantification 
To extract cellular proteins, at least 1 x 106 cells were harvested on ice, washed in ice-
cold Phosphate buffered saline (PBS) and pelleted at 500 x g for 1 min at 4°C. The cell 
pellet was resuspended in 100 µL Radioimmunoprecipitation buffer (RIPA buffer) 
supplemented with proteinase inhibitors (Aprotinin, Leupeptin, Pepstatin A, Pefabloc, 
E64 all at 1 µg / mL) and PhosSTOP phosphatase inhibitor cocktail tablets. Cells were 
left on ice for 30 min before clearing the lysate by centrifugation at 16000 x g for 10 
min. The supernatant containing the proteins was transferred into a clean 1.5 mL tube 
and protein concentration was determined using the DC protein Assay kit before 
samples were stored at -20°C. The DC protein Assay is a colorimetric assay and was 
performed according to the manufacturer’s instructions. Bovine serum albumin (BSA) 
was diluted in RIPA buffer to create a standard curve of concentrations ranging from 
0.125 mg / mL to 2 mg / mL.  
 
2.3.2 Protein separation by SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to separate extracted cellular proteins by their molecular weight. Protein 
lysates were mixed with 4 x Laemmli buffer containing 1% freshly added β-
mercaptoethanol for reduction and samples denatured by heating at 95°C for 5 min. 
Between 10 - 15 µg of total protein and 4 µL of Precision Plus Protein Kaleidoscope 
Prestained Protein Standard were then loaded on a Tris-glycine PAGE gel and 
electrophoresis was carried out in 1 x running buffer at 30 mA per gel for 75 min. Tris-
glycine PAGE gel recipes can be found in Table 2.6.  
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Table 2.6 Resolving and Stacking gel recipes for 2 gels  
 Resolving gel  Stacking gel 
 7% 10%  5% 
ddH2O 8.8 mL 7.05 mL  1.24 mL 
Acrylamide 
(30% w/v) 
3.9 mL 5.7 mL  4.36 mL 
5 x Gel buffer 4.25 mL 4.25 mL  1.9 mL 
10% APS 75 µL 75 µL  75 µL 
TEMED 22.5 µL 22.5 µL  22.5 µL 
 
 
2.3.3 Western blotting 
Following SDS-PAGE, proteins were transferred onto a nitrocellulose membrane in 1 
x transfer buffer at 400 mA for 1 h. The membrane was washed three times for 10 min 
in Tris-buffered saline containing 0.1% Tween 20 (TBST) and blocked at room 
temperature for 1 h in TBST containing 5% milk. After blocking, the membrane was 
washed again three times for 10 min in TBST before being incubated with primary 
antibodies at 4°C overnight on a rocker platform. Phospho-specific antibodies were 
diluted in TBST containing 5% BSA and all other antibodies used were diluted in 
TBST containing 5% milk.  
 
Following overnight incubation with primary antibodies the membrane was washed 
three times for 10 min in TBST and incubated with a horseradish peroxidase (HRP) 
conjugated secondary antibody for 1 h at room temperature. The membrane was 
developed after three further washes in TBST for 10 min using enhanced 
chemiluminescence (ECL) and a ChemiDoc Imaging system (Bio-rad).  
 
All antibodies and their dilutions used in this thesis can be found in Table 2.3 (page 
38). 
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2.4 Lentivirus 
2.4.1 Virus production in HEK-293T cells 
For increased safety a 3rd generation lentiviral system was used (Dull et al., 1998). The 
4 plasmids necessary for virus production are 2 packaging plasmids, one encoding Rev 
(pRSV-REV) and one encoding Gag and Pol (pMDLg/pRRE), an envelope plasmid 
encoding VSV-G (pCMV-VSV-G) and a lentiviral transfer plasmid encoding the 
insert of interest. 
 
3.5 x 106 HEK-293T cells were seeded in 100 mM cell culture dishes and grown until 
they reached 80% confluency. Culture medium was changed 4 h prior to transient 
transfection. Transfection mixture was prepared by combining 150 µL of 150 mM 
NaCl with 20 µL of 1 mg/mL Polyethylenimine (PEI) in one tube and 150 µL of 150 
mM NaCl with 4 µg of transfer plasmid and 2 µg of each of the packaging and 
envelope plasmids in a second tube. The NaCl/PEI mix was added to the NaCl/plasmid 
mix, vortexed and left for 20 min at room temperature before it was added dropwise 
to the HEK-293T cells. Medium was changed the next morning and the supernatant 
containing viral particles harvested 48 h and 72 h post transfection. Viral particles were 
concentrated on the day of harvesting by Ultracentrifugation at 4°C for 1.5 h at 25000 
rpm using an SW41Ti rotor in a Beckman Ultracentrifuge. Concentrated viral particles 
were resuspended in PBS and stored at -80°C after the second harvest.  
 
2.4.2 Determining viral titre 
To measure how many of the produced Lentiviral particles are infectious, viral titre 
was determined using HEK-293T cells. 4 x 105 HEK-293T cells were seeded in a 6 
well plate and left overnight before transduction with different amounts of the viral 
prep. The number of HEK-293T cells that were positive for vector encoded transgene 
expression (green fluorescent protein) were measured by flow cytometry 48 h after 
transduction. 
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The viral titre in transducing units (TU) per mL was calculated using the following 
formula:  
 𝑽𝒊𝒓𝒂𝒍	𝒕𝒊𝒕𝒓𝒆	[𝑻𝑼 𝒎𝑳⁄ ] = 𝒏𝒖𝒎𝒃𝒆𝒓	𝒐𝒇	𝒔𝒆𝒆𝒅𝒆𝒅	𝒄𝒆𝒍𝒍𝒔	𝒙	𝑮𝑭𝑷	𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆	𝒄𝒆𝒍𝒍𝒔	[%]𝑽𝒐𝒍𝒖𝒎𝒆	𝒐𝒇	𝒗𝒊𝒓𝒖𝒔	[𝒎𝑳]  
 
 
 
2.4.3 Transduction of mammalian cells 
For Lentiviral transduction of mammalian cells, a multiplicity of infection (MOI) ratio 
of 10 was used and the amount of virus needed for transduction was calculated 
according to the following formula: 
 𝑽𝒐𝒍𝒖𝒎𝒆	𝒐𝒇	𝒗𝒊𝒓𝒖𝒔	[𝒎𝑳] = 	𝑴𝑶𝑰	𝒙	𝒏𝒖𝒎𝒃𝒆𝒓	𝒐𝒇	𝒔𝒆𝒆𝒅𝒆𝒅	𝒄𝒆𝒍𝒍𝒔	𝒗𝒊𝒓𝒂𝒍	𝒕𝒊𝒕𝒓𝒆	[𝑻𝑼 𝒎𝑳⁄ ]  
 
Medium of target cells was changed 24 h before transduction. 0.5 x 106 cells were 
seeded in a 24 well plate in 0.5 mL of medium or 0.2 x 106 cells in a 12 well plate in 
1 mL of medium for HEK-293T cells. Virus was mixed with polybrene (8 µg/ mL final 
concentration) and added onto the cells. Cells were transduced via spinoculation at 450 
x g for 45 min at 37°C and incubated overnight. Fresh medium was added to each well 
the next morning to reduce the polybrene concentration to 4 µg/ mL. Virus containing 
medium was removed 48 h post transduction and cells were pooled and transferred 
into a T25 tissue culture flask for selection/expansion or used immediately for 
experiments.  
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2.5 Molecular biology techniques 
2.5.1 Preparation of competent cells 
Competent NEB stable E.coli cells needed for transformations were generated using 
the ‘Mix and Go’ E.coli transformation kit. Cells were prepared according to the 
manufacturer’s protocol.  
 
2.5.2 Transformation of competent E.coli cells 
Plasmid DNA was added to 30 µL of competent cells in a 1.5 mL tube and incubated 
for 30 min on ice. Bacteria were then heat shocked at 42°C for 45 sec and placed on 
ice for 2 min to recover before 500 µL of Luria Broth (LB) medium was added and 
bacteria were grown in a shaking incubator at 37°C for 45 min. Bacteria were then 
plated on a LB-Agar plate containing the appropriate antibiotic for selection and plates 
were incubated at 37°C overnight.  
 
2.5.3 Isolation of Plasmid DNA 
Plasmid DNA was isolated from E.coli after transformation and propagation. 
Depending on the starting E.coli culture volume, which was either 5 mL or 200 mL, a 
mini or maxi prep was performed using the Invitrogen PureLinkTM Quick Plasmid 
miniprep Kit/ Invitrogen PureLinkTM HiPure Plasmid Maxiprep Kit. The plasmid 
DNA isolation is based on the alkaline lysis method and was performed according to 
manufacturers instructions. Isolated plasmid DNA was resuspended in water and 
quantified by Nanodrop.  
 
2.5.4 Transfection of HEK-293T cells 
4 x 105 HEK-293T cells were seeded in a 6 well plate in 1.5 mL of medium and left 
overnight to adhere.  
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For plasmid transfections 50 µL of 150 mM NaCl was mixed with 1 µg plasmid (750 
ng if more than 1 plasmid was used) and in a separate tube 50 µL of 150 mM NaCl 
was mixed with 3 µL PEI.  
 
The NaCl/PEI mix was added to the NaCl/Plasmid mix, vortexed and left for 20 min 
at room temperature before it was added dropwise to the HEK-293T cells.  
For transfection of the ssODN HDR template the TransIT-Oligo Transfection Reagent 
was used. 250 µL Opti-MEM, 15 µL TransIT-Oligo transfection Reagent and 3 µL of 
100 µM ssODN was added to a tube, mixed by pipetting and incubated for 20 min 
before being added dropwise to HEK-293T cells.  
 
For transfection of sgRNA the Trans-IT mRNA Transfection kit was used. 250 µL 
Opti-MEM, 2.5 µg RNA, 5 µL mRNA boost reagent and 5 µL Trans-IT mRNA 
reagent were added to a tube and incubated for 4 min before being added dropwise to 
HEK-293T cells.  
 
Cells were harvested 48 h post transfection for protein or DNA isolation.  
 
2.5.5 Isolation of genomic DNA 
At least 1 x 106 cells were pelleted in a 1.5 mL tube, washed in PBS and resuspended 
in 240 µL of tail lysis buffer. 60 µL of 1% SDS and 6 µL Proteinase K (20 mg/ mL) 
were added and cells were incubated at 55°C in a heat block overnight. After the 
addition of 2 µL RNAse A (50 mg/ mL ) and a further incubation for 30 min at 55°C, 
Proteinase K was inactivated at 95°C for 10 min. Tubes were cooled on ice and DNA 
was precipitated by adding 400 µL isopropanol. Genomic DNA was then pelleted by 
centrifugation at 17000 x g for 10 min, washed in 70% ethanol and resuspended in 
water before quantification by Nanodrop.  
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2.5.6 Polymerase chain reaction (PCR)  
DNA was amplified by PCR for several different experiments including genotyping, 
colony screening, T7 endonuclease assays and cloning. PCR conditions varied 
depending on the DNA template, primer sequence, DNA Polymerase and length of 
target DNA. For the majority of PCRs, OneTaq Quick-Load 2 x Master Mix with 
Standard Buffer was used which only required the addition of a DNA template and 
primers. In a typical genomic PCR reaction 8 µL of OneTaq mix, 300 ng of genomic 
DNA and 1 µL of each primer were used. DNA was initially denatured for 2 min at 
95°C followed by 35 cycles consisting of a 30 sec denaturation step, primer annealing 
at 58°C for 30 sec and extension at 72°C for 1 min. Following a final 5 min extension 
step at 72°C the samples were cooled down to 4°C. 
 
For bacterial colony screens, bacteria were picked using a 10 µL pipette, transferred 
into 30 µL H2O and incubated for 10 min at 95°C. This was then used as a template in 
a PCR reaction.  
 
2.5.7 DNA electrophoresis 
To separate DNA fragments according to their size, agarose or polyacrylamide gel 
electrophoresis was performed.  
 
For agarose gels, agarose was weighed out and added to 1 x Tris-acetate-EDTA (TAE) 
buffer. The percentage of agarose is dependent on the DNA fragment size but in most 
cases a 1% (w/v) gel was used. The agarose was dissolved in 1 x TAE using a 
microwave and ethidium bromide (EtBr) was added before pouring into the gel tray. 
EtBr is a fluorescent dye that intercalates DNA and RNA. DNA was separated at 80 
V and visualized under ultraviolet (UV) light.  
Polyacrylamide gel electrophoresis (PAGE) was performed following a T7 
endonuclease assay (see 2.5.10) as this assay creates small DNA fragments that require 
a high resolving power and a thin gel for separation. A 12.5% PAGE gel was cast by 
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mixing 10 mL 30% acrylamide, 12.5 mL 2 x TAE, 2.5 mL H20, 150 µL APS, and 30 
µL TEMED together, pipetted between two plates and left to polymerize once the 
comb had been inserted. DNA was separated at 135 V for 90 min, stained with EtBr 
and visualized under UV light.  
 
2.5.8 DNA Restriction digest 
To digest DNA using restriction endonucleases, restriction sites were either added to 
DNA fragments by PCR or determined using a plasmid map when plasmid DNA was 
digested.  
 
Restriction digests were performed for 4 h using the appropriate endonuclease, 
recommended buffer and incubation temperature according to manufacturer’s 
instructions. Digested fragments were either gel extracted, or PCR purified using the 
Wizard SV gel and PCR clean up system.  
 
2.5.9 DNA Ligation 
Digested and purified DNA fragments or annealed and phosphorylated oligos were 
used as inserts in ligation reactions. To prevent self-ligation, digested plasmid DNA 
was dephosphorylated prior to ligation using Antarctic Phosphatase. For ligation a 
molar ratio of 1:3 of plasmid to insert was used and added to a tube with 1 µL T4 DNA 
Ligase, 1 µL 10 x T4 DNA Ligase buffer and H2O (up to 10 µL). The reaction was 
incubated either at 4°C overnight or 2 h at room temperature. After heat inactivation 
of T4 DNA Ligase at 65°C for 10 min followed by cooling down on ice, the reaction 
was used for transformation.  
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2.5.10 T7 endonuclease I assay 
To determine gene targeting efficiency of the CRISPR guides a T7 endonuclease I 
(T7E1) assay was performed. T7E1 recognizes and cleaves mismatched dsDNA. 
Whilst homoduplex DNA is perfectly paired, heteroduplex DNA normally contains 
‘bubbles’ formed by extra helical loops from unpaired regions. The T7E1 assay can be 
used as a mutation detection assay based on the ability of T7E1 to determine between 
homo- and heteroduplex DNA.  
 
When Cas9 causes a double strand break (DSB) in the targeted region this is repaired 
by non-homologous end joining (NHEJ) if a suitable template is not present. This 
repair process is error-prone and therefore leads to small insertions or deletions (indels) 
that can be recognized and cleaved by T7E1.  
 
For the T7 endonuclease I assay the CRISPR targeted region was amplified by PCR. 
The PCR product was then denatured at 95°C for 10 min in a hot-block and left to cool 
down to room temperature to allow for re-annealing. This leads to wild-type and 
modified homoduplexes as well as wild-type and modified heteroduplexes as shown 
in Figure 2.1 
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1 µL of NEB buffer 2 was added to 5 µL of the re-annealed PCR products, and 
reactions were incubated with or without the addition of T7E1 for 40 min at 37°C. The 
T7E1 will cleave heteroduplex DNA if present with different efficiency depending on 
the number of mismatched nucleotides and the flanking sequence as this affects the 
heteroduplex structure. Deletions are cleaved more efficiently than single base 
mutations.  
Figure 2.1 T7 endonuclease I assay  
Amplified DNA from edited and wild-type cells forms homoduplex wild type, 
homoduplex modified and heteroduplex fragments after denaturing and re-annealing.  
T7 endonuclease I recognises the mismatched DNA and cleaves the heteroduplex 
fragments resulting in smaller fragments. DNA incubated with T7 endonuclease I is 
separated on a polyacrylamide gel and gives an estimate of gene targeting efficiency.  
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After incubation of the DNA with or without T7E1, DNA was separated on 
polyacrylamide gel for 130 min at 80 V and analysed for the presence or absence of 
cleaved products. The presence of cleaved products after digestion with T7E1 indicates 
the efficiency of editing.  
 
 
2.6 Functional Assays 
2.6.1 Flow cytometry / Cell-sorting 
Flow cytometry is a technique that measures a cells characteristic including cell size 
and volume but can also be used to measure for example the expression of cell surface 
or intracellular molecules using fluorescent labelled antibodies or ligands for their 
detection. The technique is based on the presence or absence of fluorescence and light 
scattering signals that are measured when cells pass one or more laser beams. The 
direction of light scattered when cells pass the laser beam(s) correlates with the size of 
the cell (forward scatter) and granularity (side scatter). To separate a population from 
a heterogenous sample (cell sorting) a vibration is introduced generating waves that 
break the fluid stream into regular droplets allowing to select individual cells and 
divert them into a collection tube.    
 
Flow cytometry was used to determine the viral titre and measure cell viability using 
an Attune NxT flow cytometer whilst cell sorting was performed using a BD Aria and 
was used to isolate GFP-transduced cells from untransduced cells. Cell debris were 
excluded in a FSC-A versus SSC-A dot plot, duplets were discriminated in a FSC-W 
vs FSC-A dot plot and the remaining cell population was analysed depending on the 
application.  
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2.6.2 Apoptosis assay 
Between 0.5 and 1 x 106 cells were transferred to a 1.5 mL tube, pelleted at 100 x g for 
5 min and washed with PBS. Cells were then washed in 300 µL 1 x Annexin V binding 
buffer before being pelleted again and resuspended in 100 µL 1 x Annexin V binding 
buffer containing 5 µL Annexin V conjugated to FITC. Following incubation for 15 
min at room temperature in the dark cells were washed again in 300 µL 1 x Annexin 
V buffer. After a final spin at 100 x g for 5 min the cell pellet was resuspended in 400 
µL 1 x Annexin V binding buffer containing 7 µL of 1 µg/ mL propidium iodide (PI) 
and analysed via flow cytometry.  
 
2.6.3 Cell Proliferation assay 
CellTiter-Glo Luminescent Cell Viability Assay was used to measure cell 
proliferation. The assay determines the number of viable cells based on quantitation of 
the ATP present. The amount of ATP is proportional to the number of cells which 
allows using the assay to measure cell proliferation.  
100 µL of cultured cells (1 x 106 cells / mL seeding density) as well as 100 µL RPMI 
medium on its own as a control were pipetted in duplicates into a white 96 well plate 
and incubated with 100 µL of CellTiter-Glo reagent for 10 min on an orbital shaker to 
mix contents, induce lysis and stabilize luminescent signal. Luminescent signal was 
measured at a wavelength of 560 nm.  
 
 
2.7 Mass spectrometric analysis 
2.7.1 Phosphoproteomics  
Phosphoproteomics were performed by Vinothini Rajeeve from the lab of Pedro 
Cutillas, Barts Cancer Institute, Queen Mary University of London. 
Phosphoproteomics experiments were performed using mass spectrometry as reported 
(Casado et al., 2013; Rajeeve, Vendrell, Wilkes, Torbett, & Cutillas, 2014).  
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In brief, frozen cell pellets were lysed in 8 M urea buffer and supplemented with 
phosphatase inhibitors (10 mM Na3VO4, 100 mM β-glycerol phosphate and 25 mM 
Na2H2P2O7 (Sigma)). Proteins were digested into peptides using trypsin and 
phosphopeptides enriched from total peptides by TiO2 chromatography (Larsen, 
Thingholm, Jensen, Roepstorff, & Jorgensen, 2005)). Dried phosphopeptides were 
dissolved in 0.1% TFA and analysed using a Nanoflow UltiMate 3000 RSLCnano 
instrument coupled to a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific). 
Gradient elution was from 3% to 35% with 0.1% formic acid in acetonitrile in 120 min 
at a flow rate of 300 nL/min with 0.1% formic acid in water used to balance the mobile 
phase. The spray voltage was 1.95 kV and the capillary temperature was set to 255 ºC. 
The Q Exactive Plus was operated in data dependent mode with one survey MS scan 
followed by 15 MS/MS scans. The full scans were acquired in the mass analyser at 
375- 1500m/z with the resolution of 70 000, and the MS/MS scans were obtained with 
a resolution of 17 500. MS raw files were converted into Mascot Generic Format using 
Mascot Distiller (version 2.5.1) and searched against the SwissProt database (release 
December 2015) restricted to human entries using the Mascot search daemon (version 
2.5.0).  
Allowed mass windows were 10 ppm and 25 mmu for parent and fragment mass to 
charge values, respectively. Variable modifications included in searches were 
oxidation of methionine, pyro-glu (N-term) and phosphorylation of serine, threonine 
and tyrosine. Phosphopeptide quantification was performed using in-house software 
Pescal as described (Alcolea, Casado, Rodriguez-Prados, Vanhaesebroeck, & Cutillas, 
2012). The resulting quantitative data was parsed into excel files for further 
normalisation and statistical analysis.  
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2.7.2 Multiplexed Inhibitor Bead (MIB) Assay  
Protein lysates were prepared as described in 2.3.1 using MIB lysis buffer 
supplemented with Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail 
2+3. Samples were lysed on ice in MIB lysis buffer, sonicated 3 x 10 sec and lysates 
clarified by centrifugation at 17000 x g for 10 min at 4°C.  
 
Following protein determination assay, 2 mg of protein was further diluted in MIB 
buffer to a total volume of 3.5 mL per sample and 743 µL of 5 M NaCl was added to 
the samples giving a final concentration of 1 M NaCl. 350 µL of MIB was added onto 
each MIB column and 200 µL ECH-Sepharose slurry was added onto each block 
column before being washed with 2 mL of high salt MIB wash buffer. The block 
columns were then placed over the MIB columns and lysates were pipetted onto block 
columns. MIB columns were washed with 5 mL high salt MIB wash buffer followed 
by a wash with 5 mL low salt MIB wash buffer and a final wash with 500 µL 0.1% 
(w/v) SDS in low salt MIB wash buffer. Columns were secured with a yellow cap and 
proteins were eluted by adding 500 µL MIB elution buffer onto the columns. After 
incubating the columns for 15 min at 95°C the eluate was collected in a 1.5 mL low-
retention tube. The elution and collection using 500 µL MIB elution buffer was then 
repeated collecting the eluate in the same tube.  
 
Samples were then treated with Dithiothreitol and Iodoacetamide for reduction and 
alkylation before being concentrated. Methanol/Chloroform Precipitation was 
performed to remove the detergent before samples were trypsin digested overnight. 
The next day, ethyl acetate extraction was performed to remove Triton from the 
digested peptides and digested peptides were cleaned using C-18 PepClean spin 
columns. Samples were then analysed by Mass Spectrometry (University of Warwick). 
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Chapter 3:   Validation of BTKC481S knock-in and 
BTK knock-out strategy in HEK-
293T cells  
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3.1 Introduction 
Genome editing using programmable nucleases is a rapidly evolving field enabling 
targeted gene disruption both in vitro and in vivo. While editing has been performed 
with nucleases such as Zinc fingers (ZFNs) and Transcription activator like effectors 
(TALENs), the clustered regularly interspaced short palindromic repeats (CRISPR) - 
associated nuclease 9 (Cas9) system has become the most popular technique and has 
found its use in a variety of applications in biotechnology and medicine. When the 
Cas9 nuclease induces a double strand break (DSB) at a user-defined target sequence, 
it triggers the cells natural repair system which will attempt to repair the break either 
by non-homologous end joining (NHEJ) or homology directed repair (HDR) 
(Zaboikin, Zaboikina, Freter, & Srinivasakumar, 2017). NHEJ is an error-prone 
process that results in small insertions and/or deletions (indels) and disrupts the gene 
(Rodgers & McVey, 2016). By contrast, HDR is a more specific process which allows 
custom modifications in the presence of a suitable homologous donor template. 
  
Several CRISPR/Cas systems have been developed and characterized from different 
bacteria with each of them having their own application-dependent advantages. The 
first Cas endonuclease used successfully in human cells, which is also the best 
characterized and most commonly used Cas nuclease, is SpCas9 derived from 
Streptococcus pyogenes (Jinek et al., 2013). One advantage of SpCas9 is that its 
required Protospacer adjacent motif (PAM) for DNA binding, 3’ NGG, occurs 
relatively frequent in most genomes, resulting in many available target sites (Cong et 
al., 2013). On the other hand, the large size of the endonuclease is a major 
disadvantage, restricting some in vivo applications. Other Cas9 orthologues, including 
SaCas9, are smaller in size but require more restrictive PAMs (Komor, Badran, & Liu, 
2017). 
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Comparing the efficiency of different Cas nucleases in engineering mammalian 
genomes appears to be difficult due to differences in target size, cellular context and 
protein expression levels of performed studies. It is therefore necessary to validate and 
optimize experimental designs to achieve the best result.  
 
To date, Bruton’s tyrosine kinase (BTK), known for its role in B-cell receptor 
signalling, has not been targeted using the CRISPR/Cas system. The CRISPR/Cas 
system was chosen as the preferred method over other genome editing technologies 
due to its simplicity and efficiency. Comparing CRISPR/Cas with RNA interference 
to disrupt gene expression, CRISPR/Cas seems to be more consistent and robust and 
allows to completely block protein expression, eliminating low level protein 
expressions that can remain using RNA interference (Gilbert et al., 2014; Gilbert et 
al., 2013).   We therefore aimed to establish and validate a CRISPR/Cas strategy to 
knock-out BTK but also generate a cysteine to serine mutation in BTK at position 481 
via “knock-in”. The mutation appears in some patients treated with the BTK inhibitor 
ibrutinib and causes a secondary resistance. Establishing a strategy to knock out BTK 
and create the BTKC481S mutation will allow us to analyse the role of the protein but 
also the effects of the mutation in different cellular contexts.   
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3.2 Establishing a CRISPR-based BTKC481S knock-in strategy  
3.2.1 Design of BTKC481S knock-in guides, HDR template and genotyping 
primers 
The BTK gene, located on the X chromosome, consists of 19 exons (659 amino acids) 
with the Cys481 residing in exon 15. To mutate C481 we designed 5 different guides 
targeting exon 15. The guides recognize a specific DNA sequence and direct the Cas9 
endonuclease to this location for binding and cleavage. The cDNA sequence for BTK 
was obtained from the NCBI Unigene database 
(https://www.ncbi.nlm.nih.gov/unigene) and guides were designed using the CRISPR 
design tool at the Broad Institute                          
(https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design). Guide 
sequences and their binding location can be found in Figure 3.1. All guides are 
immediately 5’ to the Streptococcus pyogenes Cas9 (SpCas9) PAM sequence 5’ NGG 
3’ (highlighted in red). Guides were chosen both for their proximity to the target site 
C481 and low off-target score according to the Broad Institute tool. The 
PAM sequence serves as a Cas9 binding site and the double-strand break (DSB) will 
occur 3 nucleotides 5’ to the PAM site.  
 
Figure 3.1 Schematic of guides targeting exon 15 of BTK 
5 different guides targeting exon 15 of BTK were designed using the CRISPR design 
tool at the Broad institute. All guides are immediately adjacent to the SpCas9 PAM 
sequence 5’ NGG 3’. The PAM sequences are highlighted in red. 
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A Cas9-induced DSB is either repaired by non-homologous end joining (NHEJ) or 
homology directed repair (HDR). The NHEJ repair mechanism is prone to error and 
often results in insertion or deletion (indels) of bases. The HDR mechanism is more 
accurate and occurs when a homologous piece of DNA is present to act as a template. 
The HDR pathway can therefore be utilized to create specific insertions or 
modifications into the genome. 
 
For the homology directed repair of the Cas9-introduced double strand break a 111 bp 
single-stranded oligodeoxynucleotide (ssODN), containing the desired mutations, was 
synthesised and used as a template. The template was designed by changing bases of 
the BTK wild type sequence leading to a change in the amino acid at position 481 from 
Cysteine to Serine (Figure 3.2). We also introduced a number of silent mutations in 
the HDR template that would disrupt the SpCas9 PAM sequence and therefore prevent 
further editing once a successful knock-in has occurred. Because single base changes 
are difficult to detect the introduction of these additional silent mutations also allowed 
us to screen for a knock-in via PCR.  
 
Figure 3.1 Schematic of guides targeting exon 15 of BTK 
5 different guides targeting exon 15 of BTK were designed using the CRISPR design 
tool at the Broad institute. All guides are immediately adjacent to the SpCas9 PAM 
sequence 5’ NGG 3’. The PAM sequences are highlighted in red. 
Figure 3.2 BTKC481S knock-in HDR template design 
A ssODN containing silent mutations as well as necessary base changes to change the 
amino acid at position 481 of BTK  from Cysteine to Serine was designed as a HDR 
template. Silent mutations are highlighted in red showing the destruction of the 5’ 
NGG 3’ PAM sequence.  
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To genotype cells for a successful knock-in of the designed HDR template, PCR 
genotyping primers were designed and checked for specificity using the NCBI Blast 
algorithm. Figure 3.3 shows the primer binding location and expected PCR product 
sizes. Primers ex15F and ex15R span exon 15 and are outside of the targeted region 
giving an 884 bp product for wild type (WT) as well as mutated cells. MutF and mutR 
are 481S specific primers and do not bind to the WT sequence. Using these primers in 
combination with primers ex15F and ex15R will result in a 588 bp or 315 bp product 
only when the HDR template was successfully knocked in.  
 
 
 
 
 
  
Figure 3.3 BTKC481S genotyping primer design 
2 primers flanking exon 15 (ex15F, ex15R) as well as 2 BTK481S mutant specific 
primers (mutF, mutR) were designed using the NCBI Blast algorithm and used for 
genotyping. 
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3.2.2 BTKC481S knock-in using pX459 and a ssODN repair template 
To validate the gene targeting efficiency of the guides designed in 3.2.1, all 5 guide 
sequences were cloned individually into the SpCas9 endonuclease and tracrRNA- 
expressing plasmid pX459. This plasmid contains a puromycin selection marker and 
the SpCas9 endonuclease is under the control of a chicken β-actin (Cbh) promoter. 
The guide oligonucleotides were phosphorylated using T4 Polynucleotide Kinase, 
annealed and ligated into the plasmid digested with BbsI. Following transformation 
and colony screening for correctly inserted clones, plasmids were extracted and 
sequenced before being used for transfections.  
 
HEK-293T cells were then transfected with the pX459 plasmids containing the 
different guides as well as with the ssODN serving as an HDR template for the Cas9-
induced DSB. Genomic DNA was isolated 48 h post transfection and a genotyping 
PCR was performed using the primers shown in Figure 3.3. The PCR reaction was 
separated on a 1% agarose gel and compared to the expected product sizes.  
 
Figure 3.4 top panel shows the predicted agarose gel of PCR products expected from 
cells containing the BTKC481S mutation. Figure 3.4 bottom panel shows the results in 
untransfected (first 3 lanes on the left) and transfected HEK-293T cells. As predicted 
the exon-spanning primer set A gives an 884 bp product in all cells acting as a control 
for the genotyping PCR. The 588 bp and 315 bp products only occur in transfected 
cells as primer pairs B and C contain mutation-specific primers. This result confirmed 
that all 5 guides tested are able to target exon 15 of BTK and that the HDR template 
was successfully incorporated into some cells to enable detection via PCR.  
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Figure 3.4 Validation of HDR using pX459-SpCas9 and a ssODN BTKC481S HDR 
template 
HEK-293T cells were transfected for 48 h with the SpCas9 and guide expressing 
plasmid pX459 together with a ssODN HDR template to generate the BTKC481S 
mutation. Genomic DNA was isolated from untransfected and transfected cells and a 
genotyping PCR was performed using an exon 15 spanning primer set (A) as well as 
mutation-specific primers (B and C). 
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3.2.3 sgRNA delivery as in vitro transcripts  
The two CRISPR components, Cas9 endonuclease and small guide RNA (sgRNA), 
can be delivered into cells in various formats. The sgRNA can be delivered either via 
a plasmid under the control of an RNA polymerase III promoter as described in 3.2.2 
or as in vitro- transcribed/synthetic RNA. sgRNA delivery as RNA has two advantages 
over plasmid delivery. The first is the higher transfection efficiency of small RNA 
molecules in some cell lines. The second advantage is that RNAs are short-lived 
meaning that they get degraded quickly and therefore will not be passed on to daughter 
cells. This reduces the risk of unwanted mutations due to off-target binding of the 
guides. 
 
For in vitro transcription the sgRNA was amplified from the pX459 plasmid using a 
forward primer containing of a T7 promoter fused to the guide sequence and a reverse 
primer which binds to the sgRNA backbone and contains the Polymerase III stop 
signal (TTTT). The resulting PCR product has the sgRNA sequence fused to a T7 
promoter which can then be transcribed to RNA using a T7 RNA polymerase.  
 
Figure 3.5 Schematic of sgRNA amplification 
Plasmid pX459 containing the 5 different guides targeting exon 15 of BTK  was used 
as a template to amplify the sgRNA. A T7 promoter was added 5’ to the guide 
sequence to allow for in vitro RNA transcription.  
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The amplified PCR product was purified using the Wizard SV Gel and PCR clean-up 
system and the DNA was used as a template for in vitro sgRNA synthesis using a T7 
RNA Polymerase. After RNA purification and quantification by Nanodrop, a small 
amount of the sgRNA was separated on a 1% agarose gel to ensure the PCR had 
worked and was of the correct size.  
 
To supply cells with the Cas9 endonuclease, empty pX459 was then transfected into 
HEK-293T cells together with the ssODN HDR template and the 5 different 
transcribed sgRNAs. Genomic DNA was isolated 48 h post transfection and a 
genotyping PCR was performed using the primers shown in Figure 3.3. The PCR 
reaction was separated on a 1% agarose gel and compared to the expected products 
from the predicted agarose gel (Figure 3.4 top panel). Delivery of all 5 sgRNAs as in 
vitro transcripts as well as their ability to mutate the C481 residue together with the 
HDR template was successful as determined by a 588 bp and 315 bp product in 
transfected cells when using mutation-specific primers (B,C).  
 
 
Figure 3.6 Validation of HDR to generate BTKC481S knock-in cells using in vitro 
transcribed sgRNAs 
HEK-293T cells were transfected with the SpCas9 expressing plasmid pX459, a 
ssODN HDR template and in vitro transcribed sgRNAs to generate the BTKC481S 
mutation. Genomic DNA was isolated from untransfected (first 3 lanes on the left) and 
transfected cells and a genotyping PCR was performed using exon 15 spanning primers 
(A) as well as mutation-specific primers (B and C). 
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3.2.4 Exploring the use of Staphylococcus aureus Cas9 (SaCas9) to generate 
BTKC481S knock-in cells 
Though SpCas9 is the most commonly used CRISPR endonuclease it may not be the 
best for all applications mainly due to its size. Over 20 Cas9 orthologs have been 
isolated from other species so far and these orthologs may have characteristics that 
make them more suitable for certain applications. Cas9 from Staphylococcus aureus 
for example requires a more restrictive PAM sequence 5’ NGGRRT/NGRRN ‘3 but 
is around 1 kb smaller than SpCas9. The smaller size enables efficient packaging into 
adeno-associated virus (AAV) which have limitations on their packaging capacity. As 
viruses are commonly used as a delivery system for hard to transfect cells such as 
AML cell lines, we wanted to explore the possibility of using SaCas9 to generate the 
BTKC481S mutation.  
 
SaCas9 requires a different PAM sequence and tracrRNA than SpCas9 and therefore 
we had to design new guide oligonucleotides targeting exon 15. The SaCas9 PAM 
sequence 5’ NGGRRT ‘3 is more restrictive and only appeared once within exon 15 
of BTK and therefore we only designed one guide sequence (Figure 3.7).  
 
 
 
Figure 3.7 Schematic of SaCas9 guide targeting exon 15 of BTK 
Guide targeting exon 15 of BTK was designed using the CRISPR design tool at the 
Broad institute. The guide sequence is immediately adjacent to the SaCas9 PAM 5’ 
NGGRRT 3’ ( highlighted in red). 
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The guide was then cloned into the SaCas9-containing plasmid pX601which contains 
a puromycin selection marker with SaCas9 expression under the control of a 
cytomegalovirus (CMV) promoter. The guide was phosphorylated using T4 
Polynucleotide Kinase, annealed and ligated into the plasmid digested with BsaI. 
Following transformation and plasmid extraction, the plasmid was sequenced before 
being used for transfections. HEK-293T cells were then transfected with the SaCas9 
expressing plasmid pX601 containing the guide sequence together with the ssODN 
serving as an HDR template. Genomic DNA was isolated 48 h post transfection and a 
genotyping PCR performed using the primers shown in Figure 3.3. The PCR reaction 
was separated on a 1% agarose gel and compared to the expected products from the 
simulated agarose gel (Figure 3.8 left panel).  
 
As seen in Figure 3.8 (right panel) the SaCas9 and designed guide are able to target 
exon 15 of BTK. The mutations were successfully introduced as determined by the 
588 bp and 315 bp products in the transfected cells when using mutation-specific 
primers (primer pair B and C).  
 
Figure 3.8 BTKC481S HDR template knock-in using SaCas9 and a ssODN HDR 
template 
HEK-293T cells were transfected with the SaCas9 expressing adenoviral plasmid 
pX601 and ssODN HDR template to generate the BTKC481S mutation. Genomic DNA 
was isolated, and a genotyping PCR was performed using exon 15 spanning primers 
(A) as well as mutant specific primers (B and C). 
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3.2.5 Generation of an HDR template for delivery using lentivirus   
The efficiency of polymer and liposome-based transfection reagents is very low in 
haematopoietic cells. Given that the efficiency of CRISPR-mediated HDR is also 
extremely low we had to utilise a more efficient transfection method for the AML cell 
lines. A 3rd generation lentiviral system was therefore chosen for delivery of the 
CRISPR components. Thus far, the guides are cloned in the same plasmid as the Cas9 
endonuclease or delivered as in vitro transcripts with a Cas9-containing plasmid and 
the HDR template delivered separately as a ssODN. To deliver these components using 
lentivirus we required a system where the guide and HDR template are located within 
the same plasmid to ensure packaging together in the virus. Having the Cas9 nuclease 
in the same plasmid would cause issues with packaging and it would be more efficient 
if it was already stably integrated into the cells. 
  
A plasmid, pLeGO, was obtained from Addgene and modified, removing the Eu 
enhancer and replacing it with a multiple cloning site (LH MCS). A second multiple 
cloning site was added downstream of the WPRE element (RH MCS). These 
modifications would allow us to clone the HDR template and the guide RNA cassette 
(U6 promoter and tracrRNA) into the LH-MCS. The plasmid also encodes EGFP 
under the control of an SFFV promoter enabling us to monitor and select transfected 
cells using a cell sorter. 
 
The previously designed HDR template contains the necessary base changes to mutate 
the amino acid at position 481 from Cysteine to Serine but requires longer homology 
arms for use in plasmid form than needed for a ssODN delivery. To generate a bigger 
dsODN HDR template we amplified two overlapping regions from genomic DNA by 
PCR using the ssODN HDR template as primer to introduce the required mutations, a 
BTK exon 15 primer as well as two outside primers containing restriction sides (EcoRI 
and NheI) for plasmid cloning. The primer sequences and the binding sites are shown 
in Figure 3.9.  
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The two amplified overlapping PCR products were gel extracted, mixed together and 
denatured for 10 min at 95°C. The sample was slowly cooled down, allowing the DNA 
to re-anneal and then subjected to overlap PCR. This resulted in the fusion of the two 
products to form the full-length HDR template which could then be cloned into a 
plasmid for delivery. The two amplified PCR products as well as the annealed product 
are shown in Figure 3.10. 
 
 
 
 
 
 
 
 
 
Figure 3.9 Primer design to generate a plasmid-based BTKC481S HDR template 
Two primers spanning exon 15, the previously designed ssODN HDR template and a 
primer binding to exon 15 were used to amplify two products with an overlapping 
sequence of 44 bp. Ex15F EcoRI and Ex15R NheI primers contain 5’ restriction sites 
enabling cloning of the amplified PCR products.  
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Figure 3.10 Overlap PCR for amplification of a plasmid-based BTKC481S HDR 
template   
To generate a dsODN HDR template, primers amplifying exon 15 and its surrounding 
sequence were used, adding restriction sites as well as inserting the C481S mutation. 
The two overlapping amplified products D and E were denatured and re-annealed 
resulting in one DNA fragment (dsODN HDR template). 
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3.2.6 Validating the BTKC481S knock-in strategy using lentiviral constructs 
in HEK-293T cells 
The annealed 1151 bp product described in the previous section was used as a dsODN 
HDR template that could be delivered via plasmid. The dsODN was digested with 
EcoRI and NheI for cloning into the modified lentiviral plasmid pLeGO. Modified 
pLeGO contains an ampicillin resistance and an enhanced green fluorescent protein 
(EGFP) cassette flanked by two multiple cloning sites (MCS).   
 
All 5 previously tested SpCas9 guides were efficient in targeting exon 15 of BTK 
however, we decided to only clone one guide (guide #3) into the left-hand MCS in 
pLeGO together with the HDR template. Guide #3 was chosen due to its close location 
to the target site, its efficiency and because the designed HDR template destroys the 
PAM for guide#3 once successfully inserted, preventing further editing to occur. 
pLeGO containing the HDR template as well as guide #3 was sequenced before being 
used for experiments.  
 
For SpCas9 endonuclease delivery we tested two different lentiviral plasmids: a 
modified lentiCRISPR v2 plasmid and pCW-Cas9. LentiCRISPR v2 contains a 
puromycin selection marker and SpCas9 endonuclease expression is under the control 
of a spleen focus forming virus (SFFV) promoter. pCW-Cas9 contains a puromycin 
selection marker and SpCas9 endonuclease expression is under the control of the 
doxycycline-inducible Tet ON promoter.  
 
The modified pLeGO plasmid containing the HDR template and guide #3 was 
transfected with either lentiCRISPR v2 or pCW-Cas9 into HEK-293T cells. 
Transfection efficiency was checked 24 h post transfection under the microscope.  
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Figure 3.11 Reporter EGFP expression in pLeGO transfected HEK-293T cells 
HEK-293T cells were transfected with the SpCas9 expressing plasmid lentiCRISPR 
v2 or pCW-Cas9 and the EGFP expressing plasmid pLeGO containing the guide 
targeting exon 15 of BTK and the HDR template. Transfection efficiency was analysed 
24 h post transfection by examining EGFP positive cells.  
 
 
As seen in Figure 3.11, HEK-293T cells transfected with the lentiviral plasmid pLeGO 
express EGFP with no expression detected in untransfected cells.  
 
SpCas9 endonuclease expression is under the control of a Tet ON promoter in the 
pCW-Cas9 plasmid. To induce SpCas9 expression in pCW-Cas9 transfected cells we 
added 4 µg/mL Doxycycline 24 h post transfection. Untransfected and transfected cells 
were harvested 48 h post transfection and genomic DNA as well as proteins extracted. 
A Western blot was performed to determine SpCas9 and β-Actin protein expression.  
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The western blot results show that cells transfected with either lentiCRISPR v2 or 
pCW-Cas9 express the SpCas9 endonuclease. A weak SpCas9 expression was seen in 
cells transfected with pCW-Cas9 before the addition of doxycycline but higher protein 
levels were observed after the induction by doxycycline.  
 
To check for a successful knock-in of the HDR template, genomic DNA was isolated 
from transfected cells and used for genotyping. Due to the extended homology arms, 
which were necessary to present the HDR template in a plasmid, a new genotyping 
reverse primer (Ex15R2) was designed to screen for a knock-in. Ex15R2 binds outside 
of the extended HDR template to confirm that the HDR template was inserted at the 
correct location within the gene. Using the newly designed reverse primer ex15R2 in 
combination with the previously designed forward primer ex15F will amplify a 1244 
bp product in wild type as well as BTKC481S mutant cells. Using these two primers in 
combination with the 481S mutant specific primers mutF and mutR will only amplify 
a 678 bp and 588 bp product when the HDR template was successfully knocked in. 
Figure 3.12 SpCas9 expression in lentiCRISPR v2 and pCW-Cas9 transfected HEK-
293T cells 
Cells were transfected with SpCas9 expressing plasmids lentiCRISPR v2 and pCW-
Cas9. In pCW-Cas9 transfected cells, SpCas9 expression was induced by the addition 
of 4 µg/mL doxycycline. SpCas9 and β-Actin expression was determined 48 h post 
transfection.  
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Amplified PCR products from untransfected and transfected cells were separated on a 
1% agarose gel and compared to the predicted agarose gel shown in Figure 3.13 
(bottom left panel). All three predicted products were seen in transfected cells but as 
expected only one product was seen in untransfected cells as the mutant specific 
primers (mutF and mutR) do not bind to the wild type BTK sequence (Figure 3.13 
bottom right panel).  
 
These results showed that both SpCas9 expressing lentiviral plasmids are functional 
and that delivery of the HDR template via plasmid was successful. All lentiviral 
constructs tested could therefore be used to produce lentiviral particles to introduce the 
BTKC481S mutation in AML cell lines.  
 
 
 
 
Figure 3.13 BTKC481S HDR template knock-in using lentiviral constructs 
HEK-293T cells were transfected with the stable SpCas9 expressing plasmid 
lentiCRISPR v2 or the inducible SpCas9 expressing plasmid pCW-Cas9 followed by 
transfection with the guide #3 and HDR template expressing plasmid pLeGO. 
Genomic DNA was isolated, and a genotyping PCR was performed using exon 15 
spanning primers (F) as well as mutant specific primers (G and B ). 
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3.3 Establishing a CRISPR-based BTK knock-out strategy 
3.3.1 SpCas9 and Cas12a guide design to target exon 2 and exon 3 of BTK 
Besides generating and validating a strategy to knock-in BTKC481S we also wanted to 
design a BTK knock-out strategy to further study the role of BTK in AML.  
As mentioned previously, over 20 Cas9 orthologs have been characterized thus far. It 
has previously been shown that using multiple guides to knock-out genes is an 
effective strategy. The Cas9 ortholog AsCas12a which is derived from the 
Acidaminococcus sp BV3L6, is a class 2/type V CRISPR/Cas DNA endonuclease that 
has several advantages over SpCas9, particularly when it comes to multiplexing 
guides. AsCas12a recognizes a 5’ TTTV 3’ PAM sequence and creates a staggered 
overhang ~20 nt downstream of the protospacer sequence. Cleaving further away from 
the PAM sequence can prevent the PAM sequence from being destroyed during the 
NHEJ repair process allowing further editing to occur. Additionally, whilst SpCas9 
requires a crRNA and tracrRNA, AsCas12a only requires a crRNA as it processes its 
own pre-crRNA arrays. Multiplexing guides therefore becomes easier as only one 
promoter is needed to drive expression. Due to the smaller size of the AsCas12a, 
multiple guides can be cloned in the same plasmid as the endonuclease, therefore 
avoiding co-transfections of multiple plasmids which can lead to a lower transfection 
efficiency and is difficult when using lentivirus.   
 
To establish a BTK knock-out strategy we designed SpCas9 as well as AsCas12a 
guides using the CRISPR design tool at the Broad institute 
(https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design) or the 
design tool at Benchling (https://benchling.com/). Translation of the BTK transcript 
starts at the ATG site within exon 2. We therefore designed 6 guides targeting exon 2 
(2 SpCas9 guides, 4 AsCas12a guides) and 2 additional SpCas9 guides targeting exon 
3. The guides and their target binding location can be found in Figure 3.14. SpCas9 
and AsCas12a PAM sequences are highlighted in red.  
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Figure 3.14 Schematic of guides targeting exon 2 and 3 of BTK 
6 different guides targeting exon 2 of BTK and 2 guides targeting exon 3 of BTK  were 
designed using the CRISPR design tool at the Broad institute. SpCas9 guides are 
immediately adjacent to the SpCas9 PAM sequence 5’ NGG 3’ and AsCas12a guides 
are immediately 3’ of the 5’ TTTV 3’ AsCas12a PAM sequence. The PAM sequences 
are highlighted in red. 
 
We also designed 2 primer pairs which would amplify either exon 2 or exon 3 or exon 
2-3 when used in combination to screen for successful gene editing following 
transfection with the endonucleases and guides. The primer pairs and their predicted 
amplified product sizes are shown in the figure on the next page (Figure 3.15).  
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Figure 3.15 BTK exon 2 and 3 genotyping primer design 
2 primers flanking exon 2 (ex2F, ex2R) as well as 2 primers flanking exon 3 (ex3F, 
ex3R) were designed using the NCBI Blast algorithm and used for genotyping. 
 
 
3.3.2 Determining guide targeting efficiency using the T7 endonuclease I 
DNA mismatch assay  
When a Cas9-induced double strand break (DSB) is repaired through non-homologous 
end joining (NHEJ) it often leads to small insertions and deletions (indels) which will 
lead to gene disruption. These indels are too small to be resolved on an agarose gel but 
can be detected via T7 endonuclease I (T7EI) assay.  
 
Guides designed in 3.14 were either cloned in the previously described lentiviral 
plasmid lentiCRISPR v2 or in the lentiviral plasmid pY108. pY108 expresses 
AsCas12a, has a puromycin selection marker and AsCas12a expression is under the 
control of a CMV promoter. Plasmids containing the guides were then transfected as 
singles or doubles in HEK-293T cells. 
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Genomic DNA was isolated 48 h post transfection and the genotyping PCR used as a 
template for a T7EI assay. After digestion with T7EI, PCR products were separated on 
a polyacrylamide gel and compared to undigested products for additional bands.  
All guides tested were able to target exons 2 or 3 of BTK. Expected cut products and 
their sizes are shown in Figure 3.16 and were compared to the products seen on the 
polyacrylamide gels.  
 
 
 
 
 
 
 
A 
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Figure 3.16 T7 endonuclease assay for exon 2 and 3 of BTK  
Gene editing of Exon 2 and 3 was confirmed by T7 endonuclease assay after HEK-
293 cells were transfected with either one guide or a combination of 2 guides. A and 
B show DNA PAGE gel results for guides used to target exon 2 of BTK and C shows 
the result for guides used to target exon 3. Cleaved fragments can be seen for all guides 
tested after the incubation with T7 endonuclease compared to uncleaved products in 
samples without incubation of T7 endonuclease. 
B 
C 
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3.3.3 Guide multiplexing to knock-out BTK in HEK-293T cells 
Gene targeting using a single guide to generate a knock-out often results in small indels 
that are difficult to resolve from a non-modified locus and therefore additional assays 
such as the T7E1 have to be performed to assess editing efficiency. By using multiple 
guides, targeting the same gene can result in bigger deletions when the sequences 
between two induced DSBs are removed (Figure 3.17). Larger deletions can then 
easily be detected on an agarose gel after amplification of the targeted region. We 
therefore used multiple guides and picked guides #7+8 targeting exon 2 as well as 
guides #9+10 targeting exon 3 of BTK to generate BTK knock-out cells. Though 
multiplexing is easier with Cas12a the required PAM sequence was absent in exon 3 
of BTK and we had to use SpCas9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Guide multiplexing to knock-out genes 
Schematic showing multiple guides targeting the same gene resulting in a big deletion 
when the sequence between the induced DSBs is removed therefore enhancing the 
knock-out efficiency and allowing for an easy screen via PCR. 
Adapted from Addgene.org/CRISPR/guide/ 
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To avoid large expression constructs by cloning the guides into the SpCas9-containing 
plasmid, we cloned the 4 selected guides into a modified form of pLeGO which has 
had multiple cloning sites added 5’ and 3’ to the EGFP selection cassette. 
 
HEK-293T cells were then transfected with the SpCas9 expressing plasmid 
lentiCRISPR v2 as well as the guide expressing plasmid pLeGO. Genomic DNA was 
isolated 48 h post transfection and used as a template for a genotyping PCR. Exon 2, 
exon 3 and exon 2-3 were amplified using DNA from untransfected as well as 
transfected cells and separated on a 1% agarose gel. Additional smaller PCR products 
were detected in transfected cells (highlighted on the agarose gel in figure 3.18). These 
smaller products appear because of deletions within the amplified region showing that 
gene editing in exon 2 as well as exon 3 has occurred.  
 
Figure 3.18 Validating 
BTK exon 2 and 3 
multiplex editing 
efficiency  
Cells were transfected 
with 4 guides targeting 
Exon 2 and 3 (2 guides 
targeting each exon). 
DNA was isolated 12 h 
post transfection. Exon 2, 
exon 3 and exon 2-3 were 
amplified via PCR 
followed by separation on 
an agarose gel. 
 
84 
 
3.3.4 Determining BTK knock-out efficiency in HEK-293T cells using 
Western Blot 
Besides determining the BTK gene targeting efficiency on a genomic level we also 
wanted to assess BTK knock-out efficiency on the protein level. As HEK-293T cells 
do not express BTK we instead used cells transfected with a BTK expressing plasmid.  
A spleen cDNA library was used as a template to amplify the BTK gene. Restriction 
sites were included at the 5’ site of designed primers to allow cloning into pcDNA6.1 
Hygro. The plasmid was sequenced before being used for transfections to ensure it 
contains the correct sequence of the BTK cDNA.  
 
HEK-293T cells were then transfected with either the BTK expressing plasmid 
pcDNA6 and lentiCRISPR v2 alone or in combination with the guide expressing 
plasmid pLeGO. Proteins were extracted 48 h post transfection and Cas9, BTK and β-
Actin expression levels were determined via Western blot. As seen in Figure 3.19 cells 
transfected with the pcDNA6-BTK plasmid express BTK. A reduction in BTK protein 
level was seen in cells transfected with the guides targeting exon 2 and 3 of BTK 
indicating that using these 4 guides in combination is an efficient strategy to knock-
out BTK.  
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Figure 3.19 Validating BTK knock-down efficiency via Western blot  
Cells were transfected with 4 guides targeting exon 2 and 3 (2 guides targeting each 
exon) and a BTK expressing plasmid (pcDNA6-BTK). Proteins were isolated 48 h 
post transfection and Cas9, BTK and β-Actin protein expression was determined by 
Western blot.  
 
 
 
 
 
 
 
 
 
86 
 
3.4 Discussion 
The aim of this chapter was to establish and validate a CRISPR-based knock-out and 
knock-in strategy in HEK-293T cells targeting BTK. As the efficacy of the 
CRISPR/Cas system is influenced by several factors we aimed to address a few of 
those factors such as guide design, different Cas nucleases and delivery systems to 
establish a well working strategy that could be applied to other cell lines. HEK-293T 
cells were chosen for validation purposes due to their high transfectability.  
 
For the BTKC481S knock-in, overall 6 guides targeting exon 15 of BTK and an HDR 
template containing the desired mutations that we wanted to introduce, were designed. 
5 of these guides were designed for the use with SpCas9 and one of these guides was 
designed for the use with the smaller SaCas9. The several identified Cas9 orthologues 
all have their own advantages and disadvantages but their use is often limited by the 
required PAM site in the target gene. Whilst this is less of a problem when generating 
knock-outs, the requirement of a PAM in close proximity to a specific target sequence, 
when generating knock-ins, often rules the use of Cas nucleases with more difficult 
PAMs, that appear less frequent within the genome, out. Hence, only one guide could 
be designed for SaCas9 with its required 5’ NNGRRT PAM site whilst 5 guides could 
be designed for SpCas9 with the frequently appearing 5’ NGG PAM site. All 6 guides 
tested were able to target exon 15 of BTK and the C481S mutation was successfully 
introduced as determined by genotyping PCR (Figure 3.4 and Figure 3.8). 
 
It was shown that editing efficiency decreases with increasing cut-to-mutation distance 
(Paquet et al., 2016). For homozygous introductions, designed guides should therefore 
be as close as possible to the intended mutation. This means that in our case SpCas9 
guides # 1,2,3 and 5 are expected to be most efficient and SpCas9 guide #4 and SaCas9 
guide #6 are least efficient. Guide efficiency could be tested in future experiments by 
selecting positively transfected cells and performing a quantitative PCR.  
 
87 
 
The HDR template used to introduce the C481S mutation in BTK was designed as a 
111 bp ssODN with a 47 bp left homology arm and a 36 bp right homology arm. The 
28 bp between the homology arms were modified to change the bases TGC, coding for 
cysteine, to AGT, coding for serine, at position 481. Additional silent mutations were 
added around the 481 target site to allow an initial screen for a successful introduction 
by PCR using mutation specific primers before performing sequencing. Adding silent 
mutations is also recommended to destroy the PAM site or target sequence and 
therefore prevent CRISPR/Cas cutting after HDR-mediated editing has occurred. The 
silent mutations added in our HDR template destroy the PAM site for SpCas9 guides 
# 1,2,3 and 5 but not for guide # 4 and SaCas9 guide # 6.  
 
The design of the ssODN template is crucial for the knock-in efficiency and is mainly 
affected by homology arm length, homology arm symmetry and chemical 
modifications. A homology arm length between 30 and 50 nucleotides gives optimal 
knock-in efficiency (John A. Schiel, 2015) and using asymmetric arms for unmodified 
templates shows a slightly higher efficiency compared to symmetric arms (Richardson, 
Ray, DeWitt, Curie, & Corn, 2016) whilst the use of symmetric arms is recommended 
for phosphorothioate-modified DNA templates giving a higher knock-in efficiency 
than using unmodified templates (Renaud et al., 2016). Seeing that we used an 
unmodified ssODN template with asymmetric arms, knock-in efficiency could be 
improved with a modified template and symmetric arms.  
 
The method of delivery of the CRISPR/Cas system is still the major problem for its 
use. We therefore tested different delivery systems and strategies of the Cas9 nuclease, 
the guide and the HDR template aiming to find the most suitable method for delivery 
in AML cell lines.  
In general, there are three different strategies to edit genes using the CRISPR/Cas 
system. The first strategy is a plasmid-based CRISPR/Cas system, the second is 
delivery of Cas9 mRNA and sgRNA and the third is delivery of Cas9 protein and 
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sgRNA (C. Liu, Zhang, Liu, & Cheng, 2017). Here we only tested the plasmid-based 
CRISPR/Cas system using non-viral and viral plasmids as well as delivery of the 
sgRNA as in vitro transcribed RNA.  
 
Our first strategy was to deliver the SpCas9 and the guide in a non-viral plasmid 
(pX459) and the HDR template separately as a ssODN. The major advantage of non-
viral plasmids is its bio-safety but reduced pathogenicity, cheap and easy production 
are also advantages. Disadvantages are a low transfection efficiency and insufficient 
cellular uptake in some cell lines. As HEK-293T cells, in comparison to AML cell 
lines, are highly transfectable, this first strategy was mainly to validate the designed 
guides and HDR template.  
 
Transfecting cells with in vitro transcribed sgRNA rather than plasmid expressed 
sgRNA has a higher efficiency in some cell lines and reduces the risk of unwanted 
indels due to the short life of small RNA molecules. This delivery strategy worked 
well as shown in Figure 3.6 but and can be improved by combining sgRNA delivery 
with Cas9 mRNA or Cas9 proteins to give a completely DNA free option. Synthesizing 
the sgRNA adds the advantage of avoiding time consuming steps like cloning, 
sequencing and in vitro transcription. The disadvantage of using a plasmid free 
delivery is the missing selection marker and is therefore not recommended for hard to 
transfect cells or delivery methods that have a low transfection efficiency.  
 
Using viral plasmids gives a good transfection efficiency in most cell lines but their 
use can be limited due to the restrictions on their packaging capacity. Cas9 variants 
like the SaCas9 (~3.2 kb) used in this chapter, St1Cas9 ( ~ 3.4 kb) or NmCas9 (~ 3.2 
kb) are smaller than SpCas9 ( ~ 4.2 kb) and can help to overcome this problem 
(Murovec, Pirc, & Yang, 2017). Furthermore, some viral vectors including lentiviral 
vectors, allow packaging of bigger inserts without loss of packaging efficiency and 
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might therefore be more suitable than for example Adeno-associated viral vectors. 
Additionally, inserts can be packed in multiple plasmids to avoid big constructs. 
 
To generate BTK knock-out cells we designed guides targeting exon 2 as well as exon 
3 of BTK that we wanted to try as singles as well as doubles to increase the efficiency 
and make screening easier. Besides using SpCas9 we also wanted to test the efficiency 
of the Cas9 orthologue AsCas12a as it allows easy multiplexing of guides with only 
one promoter needed to drive expression. Designed guides for either Cas9 worked 
alone as well as in doubles as determined by T7E1 mismatch assay (Figure 3.16). The 
two doubles that seemed to have the highest efficiency (guide #7+8 and guide # 9+10) 
were chosen to knock-out BTK in HEK-293T cells after transfection with a BTK 
expressing plasmid. Using multiple guides, targeting the same gene, compared to using 
a single guide can result in bigger deletions. This has the advantage that larger 
deletions can then easily be detected by performing a standard PCR of the targeted 
region, avoiding the time-consuming T7E1 assay. 
 
Choosing the right delivery method and strategy as well as Cas9 endonuclease depends 
a lot on the target cell line, the target sequence and the application. We have shown in 
this Chapter that for the generation of the C481S mutation as well as the BTK knock-
out, SpCas9 is the preferred choice over SaCas9 and AsCas12a. Whilst SaCas9 has the 
advantage of a smaller size, it is not suitable for targeting Exon 15 of BTK due to the 
distance of the PAM to the mutation site. AsCas12a has the advantage of its easy use 
for multiplexing guides but is not suitable to knock-out BTK due to the absence of its 
required PAM site in Exon 3. The designed HDR template to generate the C481S 
mutation will destroy the PAM site of the chosen SpCas9 guide #3 once the template 
has successfully been introduced, preventing further editing to occur. Using lentiviral 
vectors will ensure a good transduction efficiency of the AML cell lines and the use 
of a separate SpCas9 expressing vector will allow us to generate Cas9 expressing cells 
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first and then use those cells for both, the generation of the C481S mutation as well as 
the BTK knock-out.  
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Chapter 4: Generating BTKC481S mutant AML 
cell lines  
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4.1 Introduction 
Acute myeloid leukaemia (AML) is a haematological malignancy resulting in an 
accumulation of immature leukaemic cells in the blood, bone marrow and organs, 
leading to leucocytosis and bone marrow failure (Grove & Vassiliou, 2014). Because 
of the diseases heterogeneity, AML is associated with a poor prognosis in general and 
treatment response as well as drug resistance and disease relapse varies making 
personalized therapeutic regimes even more important.  
 
Targeted genome editing using CRISPR/Cas9 can be used to study molecular 
pathways of normal as well as cancer cells helping us to better understand and identify 
dysregulated pathways and therefore contributing to drug discovery and development. 
One of the major challenges of CRISPR/Cas9 genome editing in AML cell lines is the 
delivery of the 4.2 kb SpCas9 endonuclease as well as the hard to transfect nature of 
these cell lines.   
 
Lentiviral vectors have the packaging capacity to deliver large inserts and have a good 
transduction efficiency and specificity to target AML cell lines. A disadvantage of 
using lentiviral vectors as delivery tool is the stable integration and expression of the 
transferred factors. It has been shown, both in vitro and in vivo, that CRISPR/Cas9 can 
induce mutations at sites that differ from the target site (Chew et al., 2016; Fu et al., 
2013; Hsu et al., 2013). The number of these off-target modifications is affected by 
Cas9 expression with high expression levels correlating with increased off-site 
cleavage (Fu et al., 2013). To avoid persistent expression of the Cas9 endonuclease, 
an inducible promoter like the Tet-ON promoter can be used to control expression. 
Recently, a self-limiting SpCas9 circuit was developed that removes the nuclease from 
edited cells and can therefore prevent accumulation of off-target modifications (Petris 
et al., 2017).  
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Another option is the use of Integrase-defective lentiviral vectors (IDLVs) that contain 
either class I mutations, that lead to specific integration deficiencies, or class II 
mutations, that affect several stages of the viral life cycle but are not as suitable for 
vector development (Wiskerchen & Muesing, 1995). Most commonly introduced 
mutations are in the catalytic triad of the Integrase such as residue D64 mutations and 
result in the inactivation of the enzyme. Other mutations affect Integrase DNA binding 
or multimerization and linear episome processing. The use of IDLVs compared to 
lentiviral vectors has demonstrated transient expression with a low capacity to induce 
off-target mutations (Ortinski, O'Donovan, Dong, & Kantor, 2017). 
 
In this Chapter we aimed to generate stable and inducible expressing SpCas9 MV4-
11, THP-1, OCI-AML3, HL-60 and U937 cells using a lentiviral delivery system. 
Furthermore, we wanted to use the pLeGO construct, generated in the previous 
Chapter, containing the sgRNA and HDR template to induce the BTKC481S mutation 
in those AML cell lines using a non-integrating lentiviral vector. We next wanted to 
derive a clonal population of cells containing the mutation for the functional 
characterization of the C481S mutation in AML cell lines.  
 
The five AML cell lines used for experiments were chosen based on the availability in 
the lab as well as their differential sensitivity to ibrutinib. Previous studies have shown 
that FLT-3 ITD positive AML cell lines are more sensitive to ibrutinib than FLT-3 
ITD  negative cell lines explaining the different GI50 (µM) values of 0.33, 2.1, 8.5, >10  
observed for  MV4-11, HL-60, U937 and OCI-AML3 cell lines respectively (Wu et 
al., 2016).  
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4.2 BTK expression in AML cell lines 
Prior to gene editing of BTK using CRISPR/Cas9 in the AML cell lines MV4-11, 
THP-1, OCI-AML3, HL-60 and U937 we wanted to ensure that those cell lines express 
BTK at a level that is detectable via Western blot. Proteins were extracted from all 5 
AML cell lines and BTK, pBTK (Tyr223), and β-Actin expression was determined 
(Figure 4.1).  
 
The 5 cell lines tested express BTK at similar levels and BTK appears to be active in 
these cells as shown by presence of a species when using the pBTK (Tyr223) antibody. 
Tyr223 is the autophosphorylation site within the BTK SH3 domain.  
 
 
 
 
 
 
 
 
 
As all 5 cell lines tested express the protein of interest, these cell lines are suitable to 
make stable and inducible SpCas9 expressing cells followed by generating the 
BTKC481S mutation.  
Figure 4.1 BTK expression in AML cell lines 
Cell lysates from MV4-11, THP-1, OCI-AML3, HL60 and U937 cells were extracted 
and expression of pBTK (Tyr223), BTK and β-Actin was determined by Western blot.   
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4.3 Generating stable and inducible SpCas9-expressing AML 
cell lines 
4.3.1 Determination of Puromycin concentration for selection 
A selectable marker is a common plasmid element that allows positive selection for 
cells that have taken up the plasmid which is particularly important for hard to transfect 
cell lines. The lentiCRISPR v2 and pCW-Cas9 plasmids both have a puromycin 
selection marker. We therefore needed to determine the puromycin concentration that 
would kill the untransfected cells ensuring that only cells that took up the plasmid 
survived the selection.  
 
MV4-11, THP-1, OCI-AML3, HL-60 and U937 cells were seeded in a 6 well plate 
and incubated with puromycin concentrations ranging from 1-8 µg/mL. Cell viability 
was measured every 24 h over 4 days via flow cytometry using propidium iodide (PI) 
staining.  
 
Based on the results from the puromycin kill curves (Figure 4.2) we decided to treat 
the cell lines MV4-11 and HL-60 with 2 µg/mL and the remaining cell lines (U937, 
THP-1 and OCI-AML3) with 4 µg/mL for 5 days for post transfection selection.  
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Figure 4.2 Puromycin titration in AML cell lines  
MV4-11, THP-1, OCI-AML3, HL-60 and U937 cells were treated with puromycin 
concentrations ranging from 1 µg/mL up to 8 µg/mL. Cell viability was measured 
every 24 h over 4 days via flow cytometry using propidium iodide (PI) staining (n=1).  
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4.3.2 Stable and doxycycline inducible SpCas9 expression in AML cell lines 
To generate stable and inducible SpCas9-expressing MV4-11, THP-1, OCI-AML3, 
HL-60 and U937 cells we used the lentiCRISPR v2 and pCW-Cas9 containing 
lentivirus. Cells were transduced with the lentiviral particles and positively transduced 
cells were selected with puromycin for 5 days using the concentrations determined 
previously. Cells were left to recover, post-selection, before proteins were extracted to 
determine Cas9 expression via Western blot.  
 
For cells transduced with the inducible SpCas9-expressing plasmid (pCW-Cas9) we 
had to determine the optimal doxycycline concentration required to induce SpCas9 
expression. Cells were treated for 24 h with doxycycline concentrations ranging from 
2-8 µg/mL before proteins were extracted and analysed for Cas9 expression.  
 
Western blot results showed that all AML cell lines transduced with either 
lentiCRISPR v2 or pCW-Cas9 containing virus express the SpCas9 protein (Figure 
4.3). Weaker expression levels were seen in OCI-AML3 and HL-60 cells transduced 
with lentiCRISPR v2. Little difference in Cas9 expression was seen with pCW-Cas9 
when using different doxycycline concentrations. Based on those results we decided 
to use 2 µg/mL of doxycycline to induce expression in U937 cells, 4 µg/mL for OCI-
AML3 and MV4-11 cells and 6 µg/mL for HL-60 and THP-1 cells in future 
experiments.  
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Figure 4.3 SpCas9 expression in AML cell lines 
AML cells transduced with pCW-Cas9 were treated with 2-8 µg/mL doxycycline for 
24 h whilst cells transduced with the stable SpCas9 expressing plasmid lentiCRISPR 
v2 were left untreated. Proteins were extracted and analysed for Cas9 and β-Actin 
expression (n=2, biological repeat).  
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4.4 BTKC481S knock-in in AML cell lines 
4.4.1 Determination of viral titre  
Generating knock-ins using CRISPR/Cas9 by providing a template to repair a double 
strand break (DSB) through homology directed repair (HDR) is very inefficient. It is 
therefore very important to maximise the transduction efficiency of the cells by using 
high titre viral preps and a multiplicity of infection (MOI) rate that is suitable for the 
target cell line.  
 
Viral titres can be distinguished by physical and functional means. Whilst physical 
titre assesses the amount of viral particles present in a sample, functional titre measures 
the expression of a gene carried by the transfer plasmid. The lentiviral plasmid we used 
for HDR template and guide delivery (pLeGO) carries a green fluorescent protein 
marker (EGFP). This allows us to measure the functional viral titre by Flow cytometry 
by analysing the percentage of EGFP positive cells post transduction.  
 
HEK-293T cells were transduced with increasing amounts of the concentrated viral 
prep and EGFP expression was determined after 72 h (Figure 4.4).  
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Figure 4.4 Viral titre determination in HEK-293T cells using Flow cytometry 
HEK-293T cells were transduced with different amounts of concentrated viral preps 
ranging from 0-20 µL and subjected to flow cytometry analysis measuring the 
percentage of GFP positive cells indicating the percentage of positively transduced 
cells (n=1).  
 
 
Viral titre was determined using the following formula : 
 
𝑽𝒊𝒓𝒂𝒍	𝒕𝒊𝒕𝒆𝒓	[𝑻𝑼/𝒎𝑳] = 	𝒏𝒖𝒎𝒃𝒆𝒓	𝒐𝒇	𝒔𝒆𝒆𝒅𝒆𝒅	𝒄𝒆𝒍𝒍𝒔	𝒙	𝑮𝑭𝑷	𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆	𝒄𝒆𝒍𝒍𝒔	[%]𝑽𝒐𝒍𝒖𝒎𝒆	𝒐𝒇	𝒗𝒊𝒓𝒖𝒔	[𝒎𝑳]  
   
Volume of Virus [mL] GFP positive cells [%] Viral titre [TU/mL] 
1 x 10-3 10.055 4.022 x 109 
3 x 10-3 23.818 3.176 x 109 
6 x 10-3 43.925 2.928 x 109 
12 x 10-3 52.131 1.738 x 109 
20 x 10-3 64.352 1.287 x 109 
 Mean: 2.630 x 109 
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Using a MOI of 10 and the median viral titre calculated above we calculated the 
amount of virus needed for transduction of AML cell lines as follows. 
 
𝑽𝒐𝒍𝒖𝒎𝒆	𝒐𝒇	𝒗𝒊𝒓𝒖𝒔	[𝒎𝑳] = 	𝑴𝑶𝑰	𝒙	𝒏𝒖𝒎𝒃𝒆𝒓	𝒐𝒇	𝒔𝒆𝒆𝒅𝒆𝒅	𝒄𝒆𝒍𝒍𝒔	𝒗𝒊𝒓𝒂𝒍	𝒕𝒊𝒕𝒓𝒆	[𝑻𝑼 𝒎𝑳⁄ ]  
 
𝑽𝒐𝒍𝒖𝒎𝒆	𝒐𝒇	𝒗𝒊𝒓𝒖𝒔	[𝒎𝑳] = 	𝟏𝟎	𝒙	𝟎. 𝟓	𝒙	𝟏𝟎𝟔𝟐. 𝟔𝟑𝟎	𝒙	𝟏𝟎𝟗  
 𝑽𝒐𝒍𝒖𝒎𝒆	𝒐𝒇	𝒗𝒊𝒓𝒖𝒔	[𝒎𝑳] = 𝟎. 𝟎𝟎𝟏𝟗			𝑽𝒐𝒍𝒖𝒎𝒆	𝒐𝒇	𝒗𝒊𝒓𝒖𝒔	[𝝁𝑳] = 𝟏. 𝟗 
 
4.4.2 Flow-sorting of EGFP-expressing AML cells 
To generate the BTKC481S mutation in AML cell lines we used cells that were 
previously transduced with the inducible Cas9 expressing plasmid pCW-Cas9. We 
chose to use these cells over cells transduced with the stable Cas9 expressing plasmid 
lentiCRISPR v2 because two of the cell lines that were transduced with lentiCRISPR 
v2 only showed weak SpCas9 expression post selection. Another advantage of the 
inducible system is that the SpCas9 is not consistently expressed. 
 
Cas9 expression was induced 24 h prior to transduction with the pLeGO viral preps 
containing the BTK481S HDR template and exon 15 guide #3. Cells were transduced 
with the amount of viral prep calculated in 4.4.1 giving an MOI of 10 to ensure a good 
transduction efficiency. Cells were left to recover, post transduction, before being 
flow-sorted for EGFP expression. Sorting is required to select the positively 
transduced cells. Following sorting there was a significant enrichment of EGFP 
positive cells (Figure 4.5).  
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Figure 4.5 Flow sorting of EGFP-expressing AML cells 
Following transduction with pLeGO containing the BTK481S HDR template, exon 15 
guide #3 and an EGFP selection marker, AML cell lines were flow sorted for EGFP 
expression. Dot plots show the percentage of GFP positive cells pre- and post-sort. 
The bar chart summarizes the sorting results (n=1).  
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HL-60 and OCI-AML3 cells had the lowest transduction efficiency and U937 the 
highest. The percentage of GFP positive cells post-sorting was similar between the 
different cell lines with HL-60 cells having the lowest percentage. Sorting only selects 
transduced cells, cells that have been successfully transduced with the HDR construct 
and EGFP selection marker, and therefore EGFP expression does not mean that these 
cells also contain the BTKC481S mutation, but it increases the likelihood.  
 
4.4.3 BTKC481S genotyping in GFP flow-sorted cells 
As shown in Figure 4.5 the sorted cell lines were not 100% pure as they still contained 
EGFP negative cells. As the knock-in efficiency using an HDR template is generally 
quite low we wanted to genotype the sorted cells to see if we were able to detect the 
BTKC481S mutation via PCR before growing single cell clones.  
 
Genomic DNA was isolated from AML cells pre- and post-sort and genotyping PCR 
was performed (Figure 4.6).  
 
We could detect mutant-specific PCR products in THP-1, U937 and OCI-AML3 cells. 
Only a slight increase in the band intensity was seen in U937 cells comparing pre- and 
post-sort results. No mutant specific PCR products were detected in OCI-AML3 cells 
pre-sort, but mutant specific products were seen following sorting. We could also see 
an increase in the mutant specific PCR product band intensity in THP-1 cells post-
sorting. No mutant specific PCR products were seen in MV4-11 cells post-sort. HL-
60 cells were discarded post-sort due to a contamination and therefore only pre-sort 
results are shown for this cell line.  
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Figure 4.6 BTKC481S genotyping PCR pre and post GFP flow sorting 
Genomic DNA was isolated from wild type as well pLeGO transduced cells pre- and 
post-sort and a BTKC481S genotyping PCR was performed using exon 15 spanning (F) 
as well as mutation specific (G and B) primers.  
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To ensure the HDR template was knocked-in successfully and without any further 
insertions or deletions we amplified exon 15 of BTK from wild type as well as sorted 
THP-1, U937 and OCI-AML3 cells using ex15F2 and ex15R2 primers. Following gel 
extraction and purification, the PCR products were subjected by Sanger sequencing.  
 
 
Figure 4.7 Sanger sequencing of wild type as well as sorted edited cells 
Exon 15 of BTK from wild type as well as edited EGFP positive flow sorted cells was 
amplified by PCR and subjected to Sanger Sequencing. Shown are the sequencing 
results around the 481 residue for THP-1 and OCI-AML3 cells.  
 
 
In both THP-1 and OCI-AML3 cells we could see double peaks around the 481 region 
indicating WT bases as well as bases that were knocked-in through HDR using the 
designed template.  
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No traces of a successful knock-in of the HDR template was seen in U937 cells and 
additional mutations were detected within exon 15. We therefore decided to only 
isolate single cell clones from THP-1 and OCI-AML3 cells.  
 
4.4.4 BTKC481S genotyping in isolated THP-1 and OCI-AML3 clones 
To isolate single cell clones containing the BTKC481S mutation, flow-sorted THP-1 and 
OCI-AML3 cells were seeded in 12 and 6 well plates in methylcellulose/RPMI 
medium as described in 2.2.3 and left to grow for 10-14 days. Colonies were 
transferred into a 96 well plate and expanded before genomic DNA was isolated. 
Isolated genomic DNA was then used for genotyping via PCR using exon 15 spanning 
(ex15F, ex15R2), 481 wild type specific (C481forward, C481reverse) and 481 
mutation specific (mutF, mutR) primers. We used wild type-specific primers to ensure 
that C481S mutation positive colonies were derived from a single cell and were not a 
mixture of mutant positive and negative cells. PCR products were separated on a 1% 
agarose gel and analysed for wild type and mutation specific bands.  
 
Overall two 96 well plates per cell line were screened using genotyping PCR. Results 
for wild type cells and 2 selected THP-1 and OCI-AML3 clones are shown in Figure 
4.8. The genotyping PCR shows that the clones contain the C481S mutation 
determined by the 588 bp and 678 bp mutation specific products (primer pair G and 
B). No wild type specific products (primer pair K and L) were detected for the clones. 
 
 
 
 
 
 
 
 
108 
 
 
 
 
 
 
Figure 4.8 BTKC481S genotyping in THP-1 and OCI-AML3 clones 
Genomic DNA was isolated from wild type THP-1 and OCI-AML3 cells as well as 
from two BTKC481S mutant clones for each cell line. Genotyping PCR using C481 wild 
type primer pairs (K and L) as well as a 481S mutant primer pairs (G and B) was 
performed using the isolated genomic DNA as a template. The table shows the 
expected PCR product size for each primer combination and agarose gels show the 
result of the separated PCR products. 
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To confirm a successful HDR template knock-in in the positive clones, exon 15 was 
amplified by PCR followed by gel extraction, purification and sequencing. Overall 5 
clones per cell line were sequenced and results for OCI-AML3 clones F2 and C12 and 
THP-1 clones H6 and F5 are shown in Figure 4.9.  
 
 
 
Figure 4.9 Sanger Sequencing of wild type as well as BTK481S THP-1 and OCI-
AML3 clones 
Exon 15 of BTK from wild type as well as 481S mutant positive THP-1 and OCI-
AML3 clones was amplified by PCR and subjected to Sanger Sequencing. Shown are 
the sequencing results around the 481 residue. 
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4.5 Discussion 
The aim of this Chapter was to generate stable and doxycycline inducible SpCas9-
expressing AML cell lines using lentivirus as a delivery system. This would be 
followed by the introduction of the BTKC481S mutation in exon 15 using a non-
integrating lentiviral vector in order to generate a BTK 481S expressing clonal cell 
population.  
 
After we had confirmed that the five AML cell lines we wanted to use for further 
experiments had detectable BTK and p-BTK (Y223) expression levels, we used two 
different systems, a stable and an inducible expression plasmid, to generate the 
SpCas9-expressing cell lines.  
 
Inducible gene expression plasmids allow quantitative and temporal control of the 
gene expression but depending on the expression system can be limited by the potential 
toxicity of the inducing agent, low induction expression and high basal levels under 
non-induction conditions (Lee et al., 1988). The tetracycline regulated gene expression 
system used in this thesis to generate inducible SpCas9-expressing cell lines is a very 
sensitive and a commonly used system in mammalian cell culture, mice and other 
species (Howe, Skryabin, Belcher, Zerillo, & Schmauss, 1995). Whilst stable gene 
expression systems are more useful when long-term gene expression is required for 
example for pharmacological studies, gene regulation mechanisms and gene therapy, 
those systems cannot be used if the expression or activation of the protein is toxic to 
the cells.  
 
While Cas9 expression does not appear to be toxic to the cells, constitutive or high 
expression levels have been shown to correlate with increased off-target modifications 
(Fu et al., 2013). An inducible promoter for Cas9 expression is therefore advantageous. 
Only weak Cas9 expression was detected under non-induction conditions for three out 
of the five transduced AML cell lines (MV4-11, OCI-AML3 and U937).  
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The lowest doxycycline concentration (2 µg/mL) used, was sufficient at inducing Cas9 
expression and no toxic/detrimental effects were seen for all concentrations tested 
(Figure 4.3). 
 
Delivering the guide targeting exon 15 of BTK as well as the HDR template in a 
separate plasmid to that expressing the Cas9 meant that we required a second selection 
marker. A selection marker is not required in cases when an introduced gene changes 
the phenotype of the cells allowing to isolate the subpopulation of cells that have 
incorporated the gene via flow cytometry. As this is not the case for the introduction 
of the BTKC481S mutation we decided to use GFP as a selection marker as this allows 
for easy determination of the viral titre via flow cytometry, easy monitoring of the 
transduction efficiency and sorting for positive transduced cells.  
 
The transduction efficiency was relatively low (< 10%) for all AML cell lines except 
U937 (Figure 4.5). Therefore, a range should be tested to determine the optimal MOI 
to achieve a higher transduction efficiency. Whilst this is not necessary as we 
subsequently sorted positively transduced cells, which leads to an enrichment of the 
transduced subpopulation, it does help to achieve a higher purity of the sorted 
population. Smaller subpopulations also require a lower sorting rate meaning that the 
sorting process is time consuming which increases the stress on the cells and therefore 
affects cell viability. It also increases post-sort recovery time resulting in a higher 
chance of contamination. For HL-60 cells the post-sort population only contained 
~60% GFP positive cells and cells had to be discarded due to a contamination. A purer 
post-sort population was achieved for the other AML cell lines with ~90% GFP 
positive cells. Genotyping of sorted cells confirmed successful introduction of the 
BTKC481S mutation in U937, THP-1 and OCI-AML3 cells but not MV4-11 cells. 
Whilst sorting does enrich the successfully transduced subpopulation the post-sort 
population still contained ~10% untransduced cells. Knock-in efficiency via the 
CRISPR/HDR pathway is reported to be only in the range of 0.5-20% (B. Wang et al., 
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2015) meaning that only a small percentage of the transduced cells contains the 
BTKC481S mutation and this may explain why the genotyping for MV4-11 cells was 
negative.  
 
Enhancing HDR by suppressing the NHEJ key molecules KU70, KU80 or DNA 
Ligase IV via gene silencing or small-molecule inhibition has been attempted in a 
number of studies. For example, inhibition of KU70 and DNA Ligase IV can increase 
HDR efficiency 4-5 fold (Chu et al., 2015). Another strategy is to exogenously express 
the protein Rad52, a protein involved in Homologous recombination. The combination 
of Rad52 overexpression and DNA Ligase IV inhibition using the small-molecule 
inhibitor Scr7 can improve HDR efficiency up to 40% (Shao et al., 2017). The efficacy 
of using these strategies has been mixed and so far, only small inserts and a few loci 
have been tested. It is not clear whether these strategies would enhance the BTKC481S 
knock-in and it is important to keep in mind that NHEJ inhibition alone may cause 
mutagenesis or toxicity.  
 
To ensure that cells used for further experiments do contain the BTKC481S mutation 
and have a homogenous genetic background, clonal cell populations had to be derived 
from the post-sort population. This can be achieved in a number of methods all of 
which have their own advantages and disadvantages. The limiting dilution method, a 
method for which increasing dilutions of the parent cell culture are set up, has the 
advantage of preserving cell viability but is a very time consuming process that relies 
on statistical probabilities for monoclonality and varies with changes to the protocol 
(Nakamura & Omasa, 2015). To increase the probability of obtaining a clonal 
population, cells could be seeded straight into a 96 well plate at a concentration of 1 
cell/well during the sorting process. Growing a single cell in RPMI medium or 
conditioned medium has proven to be difficult for the AML cell lines used in this 
thesis. To overcome this problem, cells were seeded in a methylcellulose-based semi-
solid medium. The viscosity of the medium keeps secreted metabolites, growth factors 
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and matrix proteins in close proximity to the clones which is fundamental for cell 
growth (Caron et al., 2009). The viscosity also minimizes cell migration resulting in 
the formation of colonies that can be easily isolated and expanded.  
 
The AML cell lines used in this thesis except the HL-60 cell line are derived from male 
patients, meaning they only carry one copy of the BTK gene, which makes the 
generation of BTKC481S mutant positive cells easier. A homogenous BTKC481S 
background of expanded clones was confirmed via sequencing and genotyping using 
wild type as well as mutant-specific primers (Figure 4.8 and Figure 4.9). Because 
additional mutations surrounding the exon 15 target site were detected in U937 cells 
the whole BTK gene should be sequenced in selected THP-1 and OCI-AML3 clones 
to ensure that clones that have been used for functional analysis do not contain 
additional mutations within the BTK gene. Any additional mutations could potentially 
change the protein conformation, its activity and expression profile. To study CRISPR 
off-target modifications, whole genome sequencing would need to be performed.  
 
In this Chapter we presented a strategy to introduce the BTKC481S mutation in five 
different inducible Cas9 expressing AML cell lines. A clonal population containing 
the BTKC481S mutation was only isolated for two out of the five cell lines due to 
technical issues, methods used that affected cell viability and low CRISPR/HDR-
mediated knock-in efficiency in those cell lines. 
 
A large number of efforts have been made to address these issues but there is still a 
long way to go to optimize the techniques and strategies for CRISPR/Cas9 to be used 
in humans.  
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Chapter 5: Functional characterization of the 
AML cells containing the BTKC481S 
mutation   
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
5.1 Introduction 
Even though advances in targeted therapy have helped to sustain therapeutic control 
of some cancer types, acquired drug resistance is still a huge problem in chemotherapy. 
Knowing about and understanding the mechanisms that cause drug resistance can help 
to counter this phenomenon. Mechanisms of acquired resistance to kinase inhibitors 
can be divided into 3 main categories: target reactivation (e.g. through a secondary 
mutation), activation of upstream and downstream effectors and activation of a bypass 
oncoprotein (Garraway & Janne, 2012). One of the most common drug resistance 
mechanism involves mutations in the targeted gene and are detected in a wide variety 
of cancer types that have been treated with kinase inhibitors. These mutations often 
exist before drug treatment and expand with the pressure of the drug (Michor et al., 
2005; Shah et al., 2002).  
 
Ibrutinib is a first in class BTK inhibitor that binds covalently and irreversibly to the 
Cysteine 481 residue in the ATP binding site. Despite good clinical efficacy in a range 
of B-cell malignancies, acquired resistance has developed in some of the patients 
treated with the drug. Mutations at the ibrutinib binding residue C481 are most 
common but other mutations such as T474I/S have also been reported. To overcome 
the ibrutinib resistance, more selective inhibitors that are efficient against these 
mutated BTK forms are needed. Recent studies have shown that while other covalent 
BTK inhibitors also display reduced potency to BTK C481 mutant forms, noncovalent, 
more selective BTK inhibitors are unaffected (Johnson et al., 2016). GDC-0853 is the 
most selective BTK inhibitor to date and does not interact with the C481 residue or the 
gatekeeper residue T474 but rather binds in an orthogonal orientation compared to the 
orientation of covalent inhibitors. GDC-0853 therefore has the potential to overcome 
acquired ibrutinib resistance and is currently being tested in a phase I clinical study in 
patients with relapsed or refractory B-cell NHL or CLL that had relapsed on ibrutinib 
(Crawford et al., 2018).  
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The aim of this Chapter was to characterize the BTKC481S mutation in AML cell clones 
derived from CRISPR/Cas9 edited THP-1 and OCI-AML3 cell lines and study the 
effects of ibrutinib in BTKWT and BTKC481S cells. We also wanted to compare ibrutinib 
with GDC-0853 regarding differences in the drugs binding mechanisms and their 
efficacy to inhibit BTK activity. Phosphoproteomics as well as a kinase binding assay 
were performed to assess differences in the expression and activation profile of BTKWT 
and BTKC481S cells treated with ibrutinib.  
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5.2 Pharmacological inhibition of BTK in BTKWT and 
BTKC481S AML cell lines 
5.2.1 BTKC481S mutation reduces the binding affinity between ibrutinib and 
BTK 
To study the functional consequences of the BTKC481S mutation in the generated THP-
1 and OCI-AML3 mutant clones we treated cells with increasing concentrations of the 
BTK inhibitor ibrutinib. Ibrutinib is an irreversible inhibitor that binds covalently to 
Cys481 blocking autophosphorylation at Tyr223 which was used as a parameter for 
BTKs enzymatic activity.  
One clone of each cell line was chosen at random (THP-1 clone H6 and OCI-AML3 
clone F2) and BTK mutant as well as wild type cells were treated for 2.5 h with 
ibrutinib concentrations ranging from 1 – 1000 nM. Protein lysates were extracted and 
p-BTK (Tyr223), BTK, p-PLCγ2 (Tyr1217), PLCγ2, p-AKT (Ser473), AKT, p-p42/44 
(Thr202/Tyr204), p42/44 and β-Actin expression levels were determined by Western 
blot.  
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Figure 5.1 Effects of ibrutinib on BTK autophosphorylation and other proteins in 
BTKWT and BTKC481S cells 
Cells were treated with indicated ibrutinib concentrations for 2.5 h after which cells 
were harvested and analysed for protein expression by Western blot. Top blots show 
results for THP-1 cells and bottom blots show results for OCI-AML3 cells (n=3 
biological repeats). 
 
 
Both cell lines exhibited constitutive phosphorylation of BTK (Y223) in untreated 
cells which was also present in BTKC481S cells (Figure 5.1). A decrease in p-
BTK(Y223) was observed with increasing ibrutinib concentrations in wild type as well 
as THP-1 mutant cells compared to untreated and vehicle treated cells. The effective 
ibrutinib concentration was 10 nM in THP-1 and OCI-AML3 wild type cells and 300 
nM in THP-1 mutant cells. p-BTK (Y223) was not inhibited in OCI-AML3 mutant 
cells even for high ibrutinib concentrations (Figure 5.1 bottom right blot).  
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A non-specific band in OCI-AML3 mutant cells as well as low expression levels in 
the selected clone made it difficult to determine p-BTK (Y223) expression levels and 
we decided to not use this clone for further experiments due to having issues 
reproducing the data. The Western blot results from THP-1 and OCI-AML3 wild type 
as well as THP-1 mutant cells indicate that higher ibrutinib concentrations are required 
to inhibit autophosphorylation of BTK in BTKC481S cells compared to BTKWT cells. A 
slight decrease in p-PLCγ2(1217) expression levels was also seen in all cell lines for 
ibrutinib concentrations > 100 nM (> 30 nM in OCI-AML3C481S cells). No changes in 
p-AKT(S473) and p-p42/44(T202/Y204) were seen in ibrutinib treated wild type or 
mutant cells.  
 
5.2.2 BTKC481S mutation leads to reversible ibrutinib inhibition of BTK 
Ibrutinib binds covalently to BTK Cys481 and it is expected that mutations of this 
residue should result in ibrutinib becoming a reversible inhibitor. 
To study whether the BTKC481S mutation affects the covalent and irreversible binding 
of ibrutinib we performed a wash out experiment. Cells were treated with ibrutinib 
concentrations ranging from 1 – 1000 nM for 2 h, washed with PBS 3 times and then 
left for another hour before cells were lysed and p-BTK (Tyr223), BTK, p-PLCγ2 
(Tyr1217) and PLCγ2 expression levels were determined by Western blot.  
A dose-dependent decrease in p-BTK(Y223) and p-PLCγ2(1217) expression levels 
was seen in all cells treated with ibrutinib (Figure 5.2). Whilst the wash out did not 
reverse inhibition of autophosphorylation of BTK at Y223 in wild type cells, the 
effects of ibrutinib seem to be reversible in BTKC481S cells as shown by detectable p-
BTK(Y223) expression levels even at high concentrations. 
In THP-1 BTKWT cells, 3 nM was effective in blocking BTK Y223 
autophosphorylation and concentrations > 3 nM were effective in decreasing p-
PLCγ2(1217) expression levels (Figure 5.2 top left blot). 
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Figure 5.2 Ibrutinib wash out experiment 
Cells were treated with indicated ibrutinib concentrations for 2 h followed by drug 
wash out and a 1 h incubation in the absence of the drug before cells were lysed and 
analysed for protein expression by Western blot (n=3, biological repeats).   
 
 
In THP-1 BTKC481S cells a slight decrease of p-BTK(Y223) was seen for ibrutinib 
concentrations > 30 nM and p-PLCγ2(Y1217) expression levels were decreased for 
ibrutinib concentrations > 3 nM compared to untreated and vehicle treated cells (Figure 
5.2 top right blot). In OCI-AML3 BTKWT cells 10 nM was effective in blocking BTK 
Y223 autophosphorylation and concentrations > 10 nM were effective in decreasing 
p-PLCγ2(Y1217) expression levels (Figure 5.2 bottom blot).  
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Comparing the Western blot results from the wash out experiment with results from 
cells treated continuously with ibrutinib for 2.5 h, it seems that the p-BTK(Y223) 
expression levels in BTKC481S cells increase. This data suggests the binding of ibrutinib 
to BTK is reversible in BTKC481S cells compared to irreversible in BTKWT cells but a 
control for the wash-out is needed to confirm those results.  
 
5.2.3 Inhibition of BTK using GDC-0853  
Unlike ibrutinib, GDC-0853 is a non-covalent, reversible BTK inhibitor that does not 
interact with the C481 residue and is the most selective BTK inhibitor reported to date. 
We wanted to compare p-BTK (Tyr223), BTK, p-PLCγ2 (Tyr1217) and PLCγ2 
expression levels in GDC-0853 treated cells with results from ibrutinib treated cells to 
see if we can overcome ibrutinib resistance in BTKC481S cells but also to confirm the 
suggested reversible binding mechanism in BTKC481S mutant cells by comparing 
results from ibrutinib and GDC-0853 wash out experiments. 
THP-1 and OCI-AML3 BTKWT and THP-1 BTKC481S cells were treated either 
continuously for 2.5 h with increasing concentrations of GDC-0853 ranging from 1 – 
1000 nM or were treated for 2 h, washed in PBS three times and incubated for another 
hour, followed by protein extraction and determination of p-BTK (Tyr223), BTK, p-
PLCγ2 (Tyr1217) and PLCγ2 expression levels by Western blot.  
Western blot results from cells treated with GDC-0853 continuously showed a dose-
dependent decrease in p-BTK (Y223) and p-PLCγ2 (Y1217) expression levels (Figure 
5.3). While GDC-0853 was similarly effective to ibrutinib in THP-1 BTKC481S cells it 
was less effective in THP-1 and OCI-AML3 BTKWT cells and even high 
concentrations (1000 nM) did not completely inhibit BTK autophosphorylation.  
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Figure 5.3 Effects of GDC-0853 on BTK autophosphorylation and p-PLCγ2(Y1217) 
Cells were treated with indicated GDC-0853 concentrations for 2.5 h after which cells 
were harvested and analysed for protein expression by Western blot. Top blots show 
results for THP-1 BTKWT and BTKC481S cells and bottom blot shows the result for 
OCI-AML3 cells (n=3, biological repeats). 
 
 
The wash out experiment showed that inhibition of BTK autophosphorylation at Y223 
can be reversed in BTKWT and BTKC481S cells as shown by higher p-BTK(Y223) 
expression levels compared to cells treated continuously with GDC-0853 (Figure 5.4). 
This data confirms the non-covalent reversible binding of GDC-0853 to BTK. 
 
123 
 
 
 
Figure 5.4 GDC-0853 wash out experiment 
Cells were treated with indicated GDC-0853 concentrations for 2 h followed by drug 
wash out and a 1 h incubation in the absence of the drug before cells were lysed and 
analysed for protein expression by Western blot (n=3, biological repeats).   
 
 
5.2.4 Ibrutinib does not effect cell viability and proliferation in THP-1 
BTKWT or BTKC481S mutant cells 
To study whether ibrutinib has any effects on cell viability and proliferation in THP-1 
BTKWT and BTKC481S cells, cells were treated with ibrutinib concentrations ranging 
from 10 – 1000 nM for 7 days. New drug was added every 48 h, cell proliferation was 
measured using the CellTiter-Glo Luminescent assay and cell viability was analysed 
by flow cytometry and AnnexinV/PI staining.  
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No decrease in cell viability was observed over the 7 days in untreated and ibrutinib 
treated BTKWT or BTKC481S cells even for the highest concentration of 1000 nM 
(Figure 5.5). This is consistent with a previous study showing that THP-1 cell viability 
is not effected by ibrutinib concentrations up to 10 µM after 72 h (Rushworth et al., 
2014).  
 
 
 
Figure 5.5 Effects of ibrutinib on cell viability 
THP-1 BTKWT and BTKC481S cells were treated with ibrutinib concentrations ranging 
from 10 – 1000 nM for 7 days and cell viability was measured by flow cytometry every 
48 h. Shown above are only the results for the highest ibrutinib concentration at 
timepoint 0 and on day 7 (n=1).  
 
 
Cell proliferation was not negatively affected by ibrutinib in BTKWT and BTKC481S 
cells as shown by the increase in the relative luminescence over time which correlates 
with the amount of ATP which in turn is proportional to the number of cells (Figure 
5.6). Cell proliferation seemed to slow down/stop after 96 h and cell density reached a 
plateau.  
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Figure 5.6 Effects of ibrutinib on cell proliferation 
THP-1 BTKWT and BTKC481S cells were treated with ibrutinib concentrations ranging 
from 10 – 1000 nM for 7 days and cell proliferation was measured every 48 h using 
the CellTiter-Glo luminescent assay (n=1). 
126 
 
5.2.6 Phosphoproteomics analysis of THP-1 BTKWT and BTKC481S cells 
As can be seen from the data above, the BTKC481S mutation does not make BTK 
refractory to inhibition by ibrutinib but rather results in reversible binding. Higher 
concentrations of the drug are therefore required to achieve maximal inhibition. We 
wanted to assess if the BTKC481S mutation only causes a change in inhibitor 
effectiveness or leads to more profound changes in kinase pathway activation. 
 
To study differences in kinase activation in untreated and 30 nM ibrutinib treated THP-
1 BTKWT and BTKC481S cells, proteins were isolated and prepared as described in 2.7.1. 
For the first analysis we used conventional phosphoproteomics which identifies 
potential kinase substrates by analysing differentially phosphorylated peptide 
sequences. A computational approach, kinase-substrate enrichment analysis (KSEA,) 
was then used to infer kinase pathway activation from phosphoproteomics data 
(Cascado et al., 2013). KSEA estimates changes in a kinase’s activity based on the 
change in phosphorylation state of its substrates as identified from phosphosite-
specific kinase-substrate databases.  
 
Analysis of the ibrutinib treated THP-1 BTKWT cells showed a decrease in the 
abundance of the NEK2 substrate group and an increase in the abundances of CDK3, 
CDK5, RPS6KA2 RPS6KA4 and TTBK1 substrate groups compared to untreated 
cells (Figure 5.7 left panel). Analysis of ibrutinib treated THP-1 BTKC481S cells 
showed a decrease in the abundances of ABL1, PLK1, LRRK1, NEK2, PHKG1, PKM, 
AKT2, CDK5 and PRKDC substrate groups and an increase in the abundances of 
CSNK1E, PRKCD, RPS6KA1, RPS6KA3 and RPS6KB1 substrate groups compared 
to untreated cells (Figure 5.7 right panel). Comparing the KSEA results from THP-1 
BTKWT and BTKC481S cells a decrease in NEK2 activity as well as an activity increase 
in kinases belonging to the RSK family can be seen in ibrutinib treated BTKWT and 
BTKC481S cells. Several other kinase subsets also seem to be differently regulated in 
BTKC481S cells upon ibrutinib treatment.   
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5.2.7 Kinome inhibitor bead profiling of THP-1 BTKWT and BTKC481S cells 
To study changes in kinase activity upon ibrutinib treatment, we used a modified 
version of a kinase capture method called multiplexed kinase inhibitor bead assay 
(Duncan et al., 2012). This is an affinity chromatography method using kinase 
inhibitors covalently linked to Sepharose beads coupled with LC-MS to detect the 
bound kinases. Both active and inactive kinases can potentially bind to the beads, 
allowing to measure kinase activation and expression. The modification of the assay 
refers to the inhibitor used. Rather than using a spectrum of kinase inhibitors the novel 
bis-anilino pyrimidine, CTx-0294885, was used. This inhibitor binds over 200 protein 
kinases therefore covering nearly 50% of the kinome (Zhang et al., 2013).  
THP-1 BTKWT and BTKC481S cells were treated with 30 nM ibrutinib for 2 h and kinase 
abundance was compared to the untreated control. Table 5.1 shows the values obtained 
from MaxQuant analysis representing the intensity/amount of each detected kinase. 0 
values were changed into the value of 1 to be included in the log2 calculations. A value 
of 0 means either that the kinase abundance was below the set threshold intensity or a 
kinase was not detected at all. Results are shown for one selected run.  
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Table 5.1 Kinase intensities in THP-1 cells obtained from MaxQuant analysis 
Gene names 
BTKWT 
untreated 
BTKWT 
treated 
BTKC481S 
untreated 
BTKC481S 
treated 
AAK1 1 2776200 1 53426000 
ATM 5496700 2457500 1 1149700 
BMP2K 1 1 1 9741800 
BTK 1 1 1 1000200 
CAMK2D 612900000 494710000 348090000 763240000 
CAMK2G 43734000 32595000 21045000 67040000 
CDK3 36722000 31611000 29293000 66747000 
CSNK2A1 1 1 1 3441800 
CSNK2A2 1 1 1 8198900 
EPHB1 1 1 1 1586200 
FES 2938400 2954500 1 16279000 
FGR 24353000 14253000 12572000 42522000 
FYN 1 1 2380500 4234300 
GAK 2948000 2599400 7512400 82588000 
GSK3B 1 1772000 1 1 
HCK 103560000 77898000 153280000 260640000 
INSR 19645000 8021900 10961000 36241000 
IRAK3 15047000 17338000 5173300 18976000 
LYN 220080000 228690000 177170000 420240000 
MAP4K1 1560900 1 1 29853000 
MAPK1 362980000 146530000 71834000 126460000 
MAPK10 1 1 1 2221800 
MAPK3 68626000 29738000 16118000 31845000 
NEK9 14651000 3972000 3423100 35490000 
PHKG2 55045000 16581000 34151000 59533000 
PKMYT1 15613000 10799000 9609200 23426000 
PKN1 15834000 7352500 3053100 37087000 
PKN2 1 1 1 5000600 
PRKAA1 9674700 3558300 6885400 21006000 
PRKACB 11334000 5700900 2323700 17376000 
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PRKCA 9203200 1 12790000 13975000 
PRKCB 26296000 2391900 1050400 6056700 
PRKDC 900850000 1160500000 356280000 1344900000 
PTK2B 1 1 1 5432000 
PTK2B 4806600 9319500 1 88975000 
RET 643410 1 4492500 54366000 
RPS6KA1 3552000 13557000 4818700 85741000 
RPS6KA3 1 1 1 2282100 
RPS6KA4 1 1 1 1925900 
SRC 48046000 55230000 39620000 159680000 
STK38 1 1 1 4389100 
TAOK3 1 1 2261500 10028000 
TBK1 25420000 28602000 11086000 95186000 
TGFBR1 12224000 11048000 26895000 79738000 
TYK2 1 1 1 4736800 
ULK3 6843600 4162600 2603500 22299000 
YES1 2083300 1 1994600 3608300 
 
 
The heatmap shows the log2 values for treated/untreated THP-1 BTKWT and BTKC481S 
cells calculated using the values from table 5.1. Red represents a decrease, green an 
increase in kinase abundance and grey represents ratios based on no data for at least 
one of the conditions (Figure 5.8). Figure 5.9 shows the same log2 values as seen in 
the heatmap but kinases with a value of 0 for one of the conditions were not considered. 
The Figure legend only shows the kinases that had an abundance difference of 2.0 or 
higher comparing BTKWT and BTKC481S cells. Figure 5.8 and 5.9 show that the 
abundance for the majority of detected kinases decreases upon ibrutinib treatment in 
THP-1 BTKWT cells but increases in BTKC481S cells.  
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Figure 5.8 Heatmap depicting changes in kinase abundances 
THP-1 BTKWT and BTKC481S cells were treated with 30 nM ibrutinib for 2 h, after 
which cells were lysed and kinases isolated using inhibitor bead analysis by mass 
spectrometry. The heatmap represents the change in log2 values of treated versus 
untreated cells with red indicating a decrease, green indicating an increase in kinase 
abundance and grey representing ratios based on no data for at least one of the 
conditions (n=2, biological repeats). 
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Figure 5.9 Dot plot representing changes in kinase abundances 
The dot plot represents the change in log2 values of treated versus untreated cells with 
negative values indicating a decrease and positive values indicating an increase in 
kinase abundances (n=2, biological repeats). 
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5.3 Discussion 
The aim of this Chapter was to characterize the BTKC481S mutation in THP-1 and OCI-
AML3 clones derived from CRISPR/Cas9 edited cells and study the effects of 
ibrutinib. 
 
One clone of both cell lines was selected at random and used for further experiments. 
Insertion of the BTKC481S mutation was confirmed by PCR and Sanger sequencing in 
the previous chapter but as only part of the gene was sequenced, we needed to ensure 
that the cells still express functional BTK. Protein lysates were extracted from 
untreated as well as ibrutinib treated (1 – 1000 nM) BTKWT and BTKC481S cells and p-
BTK (Tyr223), BTK, p-PLCγ2 (Tyr1217), PLCγ2, p-AKT (Ser473), AKT, p-p42/44 
(Thr202/Tyr204), p42/44 and β-Actin expression levels were determined by Western 
blot. PLCγ2, AKT and p42/44 are known downstream targets of BTK in B-cells and 
we wanted to assess whether pharmacological inhibition of BTK affects these 
downstream targets in AML cells also. Results showed a decrease in p-BTK (Y223) 
for BTKWT and BTKC481S cells treated with increasing ibrutinib concentrations but 
higher concentrations were required to achieve a p-BTK(Y223) inhibition in BTKC481S 
cells (Figure 5.1). These results are in agreement with previously published data 
showing that ibrutinib is less effective against BTKC481S mutant. In this study ibrutinib 
showed an IC50 of 0.72 nM against purified BTKWT and an IC50 of 4.6 nM against 
purified BTKC481S (Johnson et al., 2016). Another study showed that in a cellular model 
using HEK-293T cells ibrutinib’s half maximal effective concentration was higher in 
BTKC481S mutant cells than BTKWT cells (Woyach et al., 2014). In our cell culture 
model ibrutinib was 10-30 fold less potent against BTKC481S compared to BTKWT 
showing a greater difference between BTKWT and BTKC481S than observed with 
purified proteins.  
 
The role BTK plays in AML cells is currently unclear, however a slight decrease in p-
PLCγ2 (Tyr1217) was seen for higher ibrutinib concentrations (>30 nM) in BTKWT 
134 
 
and BTKC481S cells suggesting it may be a downstream target of BTK in AML (Figure 
5.1). No effects of ibrutinib treatment in THP-1 and OCI-AML3 BTKWT or BTKC481S 
cells were seen with p-AKT (Ser473) and p-p42/44 (Thr202/Tyr204). This is in 
agreement with previous studies showing that ibrutinib does not affect expression of 
p-AKT and p-p42/44 in OCI-AML3 and TF-1 cell lines but interestingly 
phosphorylation of these proteins is affected by ibrutinib in U937, MV4-11 cells and 
some primary AML blasts (Pillinger et al., 2015; Rushworth, Murray, Zaitseva, 
Bowles, & MacEwan, 2014). The heterogenous background of the disease could 
explain the differences seen in cell lines and patient samples and suggests a role of 
BTK upstream of PI3K/AKT and ERK signalling at least in some AML cell 
lines/blasts. Other proteins found to be regulated by BTK in AML include STAT5, 
RAC1, p65 (NF-κB subunit), MYC and NF-κB with FLT3-ITD and TLR9 being 
placed upstream of BTK (Nimmagadda et al., 2018; Oellerich et al., 2015). Recently, 
mutated granulocyte-colony stimulation factor receptors (G-CSFR) were implicated in 
upregulation of BTK in BaF3, murine 32D and c-Kit+ cells and human CD-34+ cells 
(Dwivedi et al., 2018). Further findings supported the suggested hypothesis that cells 
expressing mutant receptor are dependent on BTK activation and ibrutinib can 
therefore suppress these cells. Such mutations have been found in AML patients and 
it would be of interest to see the effects of ibrutinib in AML cell lines carrying 
mutations in G-CSFR and BTK. 
 
As ibrutinib failed to inhibit p-AKT and p-p42/44 in THP-1 and OCI-AML3 BTKWT 
or BTKC481S cells the results for the proliferation as well as cell viability assay were as 
expected. For both assays THP-1 cells were treated with ibrutinib concentrations 
ranging from 10 – 1000 nM for up to 168 h and cell proliferation was measured every 
48 h using CellTiter-Glo assay with cell viability being analysed by flow cytometry 
and Annexin-V/PI staining. No effects were seen on cell proliferation or viability 
(Figure 5.5 and Figure 5.6). Pharmacological inhibition of BTK as well as BTK 
knockdown using shRNAs can affect cell proliferation and induce apoptosis in some 
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AML cell lines (MV4-11, MOLM-13, KG-1 and NB4) and patient-derived AML 
cultures (Oellerich et al., 2015). 
 
Two FLT3-dependent mechanisms have been described so far. In FLT3-ITD negative 
cells, TLR9 is an activator of BTK and NF-κB and STAT5 are activated downstream 
of BTK whilst in FLT3-ITD positive cells MYC and STAT5 are activated downstream 
of BTK.  
Because THP-1 and OCI-AML-3 cells are FLT3-ITD negative it would be interesting 
to see whether TLR9 activates BTK in these cells or not. Downstream targets are likely 
to be different seeing that no effects on proliferation and viability were observed in 
these two cell lines. 
 
To study ibrutinib’s binding mechanism in BTKWT and BTKC481S cells we performed 
a drug wash-out experiment. Cells were incubated for 2 h with various ibrutinib 
concentrations, the drug was washed out using PBS and the cells were incubated for 
another hour in the absence of the drug before proteins were extracted. Because no 
effects on p-AKT and p-p42/44 were seen in the previous experiment under continuous 
drug exposure we only assessed effects on p-BTK and p-PLCγ2. As described before, 
we did see a decrease in p-PLCγ2 in both THP-1 and OCI-AML3 BTKWT and 
BTKC481S cells for ibrutinib concentrations > 3 nM (Figure 5.2). Ibrutinib’s binding to 
BTKWT is irreversible and covalent by nature explaining why p-BTK is still inhibited 
after washing out the drug. Interestingly in THP-1 BTKC481S cells p-BTK expression 
levels return to almost basal levels one hour after washing out the drug suggesting a 
reversible binding of ibrutinib to BTKC481S which was previously shown in DT40 
(BTK-/-) chicken B-cells transfected with exogenous BTKC481S (Woyach et al., 2014).   
 
Several second generation BTK inhibitors have been developed to reduce off target 
effects as well as to overcome the resistance caused by the BTKC481S mutation. Among 
these inhibitors is GDC-0853 which is the most selective BTK inhibitor to date.  
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Unlike ibrutinib, GDC-0853 does not bind to EGFR or ITK which are two targets of 
ibrutinib that are likely to be responsible for adverse events seen in ibrutinib treated 
patients. To study the potential of GDC-0853 to inhibit BTKWT and BTKC481S in AML 
cells we treated THP-1 and OCI-AML3 BTKWT and BTKC481S cells either continuously 
for 2.5 h with different drug concentrations ranging from 1 – 1000 nM or the drug was 
washed out with PBS after 2 h and cells were incubated in the absence of the drug for 
another hour before proteins were isolated. The wash-out experiment was performed 
to confirm the noncovalent binding of the drug to BTK. Results showed that GDC-
0853 was efficient in decreasing p-BTK(Y223) expression levels but higher drug 
concentrations are needed compared to ibrutinib in BTKWT cells. In THP-1 BTKC481S 
cells GDC-0853 showed a similar efficiency (Figure 5.3). As with ibrutinib, higher 
GDC-0853 concentrations are needed to inhibit p-BTK(Y223) in BTKC481S cells than 
BTKWT cells meaning that both drugs are equally efficient in our cell culture model 
using the generated THP-1 BTKC481S cells. These results are surprising as GDC-0853 
has been reported to be highly potent in isolated primary human B-cells, inhibiting 
BTK autophosphorylation (Y223) with an IC50 of 3.1 nM and human whole blood with 
an IC50 of 11 nM (Crawford et al., 2018). In this same study GDC-0853 successfully 
inhibited p-BTK(Y223) autophosphorylation at 1000 nM in HEK-293 cells transfected 
with BTKWT and BTKC481S whilst ibrutinib failed to do so in BTKC481S cells which is 
also not in agreement with our results.  
 
 A slight decrease in p-PLCγ2 (Y1217) was observed in GDC-0853 treated cells 
confirming it as a downstream target of BTK in the AML cell lines. The wash out 
experiment confirmed noncovalent binding as the inhibition was reversed and p-BTK 
expression levels returned to nearly basal levels after 1 h (Figure 5.4). While GDC-
0853 showed a similar efficacy at inhibiting BTK in BTKWT and BTKC481S cells its 
efficiency was lower in BTKWT cells compared to ibrutinib. As GDC-0853 is more 
selective than ibrutinib with reduced off-target binding and side effects, it is still a 
good alternative to ibrutinib and could be used especially in relapsed patients.  
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Not much is known about the role of BTK in AML and some of the known downstream 
targets are not affected by BTK inhibition in the cell lines we used. In order to identify 
additional substrates, we performed phosphoproteomics as well as a kinome inhibitor 
pulldown assay in THP-1 BTKWT and BTKC481S cells.  
 
The high throughput and quality of MS-based techniques to measure phosphorylation 
has replaced the traditional method using immunochemical techniques. The high data 
output of phosphoproteomics data however poses an analysis challenge. Publications 
using the kinase substrate enrichment analysis (KSEA) are few and the depth by which 
KSEA can derive information about kinase activation is limited by the available 
databases of kinase substrate relationships (Casado et al., 2013). Whilst these 
databases contain experimentally verified interactions, computational approaches such 
as NetworKIN have been developed to help us understand and predict kinase substrates 
from motif analysis and functional context derived from STRING (von Mering et al., 
2003).  
 
The second MS-based approach we performed was a quantitative proteomics approach 
using inhibitor beads as a method of affinity enrichment and is a useful tool when 
kinases are only present at low abundances. The downside of using beads is that the 
elution step is often inefficient resulting in a low recovery. The elution method we 
used (SDS wash) requires additional purification steps to remove the detergent and 
using SDS leaves residual enzymatic activity which can affect the measurement 
(Bischoff, Shi and Kennelly, 1998; Duncan et al., 2012). On-column trypsin digestion 
has recently been described as an elution method which improves protein yield and 
could be used alternatively in the future (Toth et al., 2017).  
 
The inhibitor used for kinase enrichment, CTx-0294885, is modified from the FAK 
inhibitor TAE-226. CTx-0294885 alone identified 235 kinases in a large scale kinome 
profiling experiment in MDA-MB-231 cells and a total of 261 kinases were identified 
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using the inhibitor in combination with 3 other inhibitors (Purvalanol B, SU6668, and 
VI16832) revealing 72 kinases that are unique to CTx-0294885 (Zhang et al., 2013). 
Even though a cross-screen profiling against 131 kinases using the chemically related 
inhibitor CTx-0294857 at a concentration of 1 µM displayed high potency against 
BTK, we were only able to identify BTK in ibrutinib treated THP-1 BTKC481S cells but 
not untreated or THP-1 BTKWT cells. Overall only 47 kinases were identified in our 
studies with only 23 kinases being identified in BTKWT and BTKC481S cells for both 
conditions therefore showing very inconsistent results between the different samples.  
 
Taken together the limited results from the KSEA and inhibitor bead assay we saw an 
increase in kinases belonging to the RSK family in both THP-1 BTKWT and BTKC481S 
cells and an increase in abundance of PKC family members in the BTKC481S cells. 
Kinase substrate enrichment analysis showed a decrease in NEK2 activity in THP-1 
BTKWT and BTKC481S cells. Only discussed here are kinases for which both assays 
showed similar results or for which similar changes were seen in wild type as well as 
mutant cells within the same assay. RPS6 has previously been shown to be activated 
in FLT3-mutated AML cells and to mediate its antiapoptotic function through 
phosphorylation of  the BH3-only protein BAD (Chen et al., 2010; Yang et al., 2005). 
RPS6KA1 was also identified as one of the top 10 kinases and a strong candidate as a 
target from drug response data from AML primary cells using AML 2.1 network 
properties and the KIEN analysis (Ong et al., 2015). The classical PKC family 
members are involved in pro-survival signalling and chemoresistance in leukaemia 
cells (Redig and Platanias, 2007, 2008). Elevated PKC β expression levels have been 
found in AML cell lines and blasts and inhibition of the kinase using enzastaurin was 
found to induce apoptosis but the mechanism of cell death does likely not involve PKC 
β (Ruvolo et al., 2011). NEK2 is a mitotic kinase involved in the regulation of cell 
cycle progression. NEK 2 has been found to be overexpressed in a variety of human 
cancers including leukaemia but the role of NEK2 in AML has not been studied yet.  
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Unfortunately, time restrictions only allowed us to perform these limited experiments. 
Additionally, the lack of an internal control is making it difficult to identify what 
effects observed are based on natural variation between experiments such as loading 
and sample processing and what changes in expression levels are actually down to the 
treatment and the mutational status. Experiments should therefore be repeated using 
one sample as a control for all runs allowing to normalize across the different 
experiments.  
Conformation of target proteins should be performed by Western blot analysis. 
Western blot analysis of the elution samples from the beads could be performed to 
confirm successful pull down of BTK before performing mass spectrometry analysis. 
The affinity assay would also benefit from using multiple inhibitors as in the original 
studies (Duncan et al., 2012).  
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Chapter 6: Perspectives and future work 
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CRISPR – Does one size fit all? 
The discovery of the CRISPR/Cas9 system as a gene editing tool is revolutionizing 
many areas of biomedical research including gene therapy, model cell line 
development, disease target identification and genomic screening. Its simplicity and 
flexibility to target nearly any location within the genome explains its popularity and 
widespread use. While other genome editing tools such as ZFNs and TALENs, have 
their own advantages, they lack the versatility of CRISPR and require more complex 
molecular biology expertise. The CRISPR/Cas9 system has its own drawbacks and 
there are several factors affecting its efficacy that still need to be addressed. Among 
these factors are target site selection, guide design, off- and on-target cleavage, HDR 
and NHEJ efficiency and how to deliver the required components. Even though the 
CRISPR technology has been used to create gene knock-out and knock-ins in human 
cell lines, animal models and nonviable human embryos, these issues preclude it from 
being used therapeutically.  
 
The work described in this thesis can be used as an example for some of the issues. 
Even though the same strategy was used, differing knock-in efficiencies were observed 
between the five AML cell lines used. We successfully generated THP-1 BTKC481S 
cells but the knock-in efficiency was too low in for example MV4-11 cells to isolate a 
mutation positive clone. Besides a low knock-in efficiency we also detected additional 
mutations in U937 cells in the BTK gene close to the target site showing the 
importance of sequencing the whole gene before and after targeting. If, and when, 
CRISPR is used for gene therapy the differences between patient DNA needs to be 
taken into account and therapy has to be individualized for safe and efficient usage.  
 
For in vitro applications we, and others, have demonstrated that CRISPR is indeed a 
very powerful tool to precisely change the DNA sequence at a target location or 
prevent gene expression by generating knock-outs. Generating knock-outs using 
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CRISPR/Cas9 is advantageous over for example using shRNAs as it is permanent and 
guarantees a 100% knock-out efficiency by selecting a single cell clone containing the 
desired changes whereas the knock-down efficiency using shRNAs varies. Delivery of 
the CRISPR components is still the greatest obstacle even though several methods are 
available. We show here that by selecting the right delivery and selection strategy even 
hard to transfect cells can be edited using CRISPR allowing the study of proteins and 
drug resistance-related mutations by modifying gene expression levels and generating 
loss- or gain-of-function mutations. As the CRISPR field is developing so rapidly the 
outlook is certainly positive and current limitations are being addressed.  
 
Is BTK a Potential Therapeutic Target in AML? 
A phase 2 clinical trial into the effectiveness of ibrutinib in AML patients was 
undertaken following our group’s unveiling of a role of BTK in AML (Cortes et al., 
2015), however the trial was closed as there was no discernible improvement of AML 
patients with ibrutinib therapy either alone or in combination with standard therapy. 
There may be a role for BTK in AML in future, and indeed there are companies 
developing dual BTK/FLT3 inhibitors for the treatment of AML (Aptose Biosciences).  
Furthermore, information gained about BTK mutation-induced adaptations, will serve 
in lymphoid leukaemia drug-resistance mechanisms too. 
 
The mutational landscape of AML is often complex and BTK is only one of the many 
kinases that has been found to show abnormal activity in AML. BTK is a protein of 
interest and our experiments in THP-1 and OCI-AML3 cell lines contribute to 
understanding the role BTK plays in those cell lines but more studies are required to 
investigate whether it has potential as a therapeutic target in the future or not. AML, 
being a disease with a heterogenous background, it makes it more difficult to interpret 
results as they do differ between different cell lines and between patient samples. If  
BTK is considered as a therapeutic target it will most likely be for a specific 
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cytogenetic/molecular abnormalities profile and as a combination therapy rather than 
a single agent. 
Targeting BTK in AML appears most promising in FLT3-mutated AML and, as 
recently reported, in AML with G-CSFR mutations (Dwivedi et al., 2018). Even 
though the BTKC481S mutation that we generated in AML cell lines using 
CRISPR/Cas9 does currently not appear in AML it still gives us the opportunity to 
study the drug resistance mechanism. Using CRISPR/Cas9 to generate mutations 
involved in drug resistance allows us to study those mutations and related effects to 
understand and overcome resistance mechanisms and find alternative therapeutic 
approaches.  
 
Future work 
In this thesis we successfully established a CRISPR/Cas9-based strategy to knock-out 
and generate a specific point mutation in the BTK gene, known as BTKC481S. The 
strategy was established and validated in HEK-293T cells before being used in AML 
cell lines. Due to time constraints and technical issues only BTKC481S mutant AML 
cells but not BTK knock-out cells were generated. This should be done in future 
experiments as it allows us to use these cells and the ‘kinomics’ approaches to compare 
the effects of  knock-out with pharmacological inhibition of BTK. As BTKs role in 
AML is unclear it would help us to identify which effects are caused by CRISPR off-
target effects, drug off-target binding or suppression of BTK expression itself.  
 
Additional mutations close to the target site were detected in the BTK gene in U937 
cells. Low BTK expression levels and additional Western blot bands when using p-
BTK (Y223) and BTK antibodies in OCI-AML3 BTKC481S cells were also observed. 
Whether this was caused by on-/off target effects or can be explained by clonal 
diversity would need to be analysed in further experiments. Whilst it is not realistic to 
do whole genome sequencing for every cell line that has been edited, targeted genes 
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should be fully sequenced to rule out any additional mutations that could affect protein 
expression, activity and conformation.    
 
To provide the correct parental control for any experiments performed a single clonal 
cell should be selected and used for gene editing rather than editing a heterogenous 
population of cells. Although this would be time consuming with two rounds of clonal 
selection, it would help to reduce the ‘noise’ seen in kinome analysis.  
 
Phosphoproteomics as well as the kinase assay were only performed once due to time 
constraints and should therefore be repeated as well potential substrates validated by 
Western blot. Cell proliferation and viability assays were also only performed a limited 
number of times and should be repeated. Fresh ibrutinib could be added to the cells 
every 24 h instead of every 48 h.  
 
To better understand the role of BTK in AML and its potential as a therapeutic target 
more experiments need to be performed. Generating AML BTK knock-out cells as 
well as generating the BTKC481S mutation in other cell lines is a good starting point. 
Especially MV4-11 cells that contain a FLT3-ITD mutation are of interest seeing that 
inhibition of BTK does affect cell proliferation and induces apoptosis in these cells 
(Oellerich et al., 2015). Some kinases that could be potential targets in AML were 
identified in Mass spectrometry analysis and should be studied further to explore their 
potential for combination therapy. 
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Figure A1 LentiCRISPR v2 plasmid 
LentiCRISPR v2 plasmid is a lentiviral SpCas9-expressing plasmid purchased from 
Addgene (#52961). The original EF-1α core promoter was replaced with a SFFV 
promoter. For guide cloning, the plasmid was digested with BsmBI to remove the 
stuffer region and annealed, guide oligos were ligated into the plasmid. 
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Figure A2 pCW-Cas9 plasmid 
pCW-Cas9 plasmid is a doxycycline-inducible lentiviral SpCas9 expressing plasmid 
purchased from Addgene (#50661). Cas9 expression is under the control of a Tet-ON 
promoter.   
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Figure A3 pLeGO plasmid 
pLeGO is a lentiviral plasmid purchased from Addgene (#27341) that expresses EGFP 
under the control of a SFFV promoter. This plasmid was modified by adding two 
multiple cloning sites (LH and RH MCS depicted in red) flanking the EGFP selection 
cassette. The additional restriction sites allowed us to clone guide#3 and the HDR 
template in the LH MCS using NheI and NotI. This plasmid was also used to clone 
guides #7,8,9 and 10 including U6 promoters and the gRNA scaffolds. 2 guides were 
cloned into the LH MCS using NheI and NotI and the other two guides were cloned 
into the RH MCS using KpnI and PvuII. 
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Figure A4 pX459 plasmid 
pX459 is a SpCas9-expressing plasmid under the control of a Cbh promoter purchased 
from Addgene (#62988). Guides were cloned into the plasmid digested with BbsI 
adjacent to the gRNA scaffold sequence.  
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Figure A5 pX601 plasmid 
pX601 is an Adeno-associated viral plasmid that expresses SaCas9 under the control 
of a CMV promoter. pX601 was purchased from Addgene (#61591) and guide#6 was 
cloned into the plasmid digested with BsaI.  
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Figure A6 pcDNA6 plasmid 
The pcDNA6 plasmid was a kind gift from Dr. Nicholas Harper. The BTK gene was 
amplified from a spleen cDNA library adding restrictions sites for cloning into the 
plasmid digested with BamHI and EcoRV.   
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